[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1454
6. Park YB, Lee JW, Cho BS, Min WS, Cheung DY, Kim JI, Cho SH, Park SH, Kim JK, Han SW: Incidence and etiology of overt gastrointestinal bleeding in adult patients with aplastic anemia. Dig Dis Sci; 2010 Jan;55(1):73-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and etiology of overt gastrointestinal bleeding in adult patients with aplastic anemia.
  • Patients with thrombocytopenia caused by various neoplastic and primary bone marrow diseases are susceptible to major hemorrhage.
  • The incidence of GI bleeding was 6.3% (32 of 508 patients) in adult patients with aplastic anemia.
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Risk Factors. Thrombocytopenia / complications. Young Adult


7. Knowles B, Bellamy CO, Oniscu A, Wigmore SJ: Hepatic resection for metastatic endometrioid carcinoma. HPB (Oxford); 2010 Aug;12(6):412-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This article describes a tertiary hepatopancreatobiliary unit's experience with hepatic resection for liver metastases from endometrioid primaries.
  • METHODS: Five women in whom liver metastases developed at 11 months to 10 years post-primary resection are presented.
  • RESULTS: Outcomes in this patient series support hepatic resection in the face of isolated liver metastasis.
  • [MeSH-major] Carcinoma, Endometrioid / surgery. Endometrial Neoplasms / surgery. Hepatectomy. Hysterectomy. Liver Neoplasms / surgery. Ovarian Neoplasms / surgery. Ovariectomy
  • [MeSH-minor] Adult. Aged. Databases as Topic. Disease-Free Survival. Female. Humans. Middle Aged. Scotland. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1997 Jul;66(1):45-51 [9234920.001]
  • [Cites] Surgery. 1997 Jun;121(6):625-32 [9186462.001]
  • [Cites] Ann Surg. 2005 Feb;241(2):269-76 [15650637.001]
  • [Cites] J Minim Invasive Gynecol. 2005 May-Jun;12(3):196-200 [15922974.001]
  • [Cites] Ann Surg Oncol. 2005 Jun;12(6):459-66 [15886903.001]
  • [Cites] Cir Esp. 2006 May;79(5):310-2 [16753122.001]
  • [Cites] Ann Surg. 2006 Oct;244(4):524-35 [16998361.001]
  • [Cites] Ann Surg Oncol. 2008 Jan;15(1):207-18 [17963007.001]
  • [Cites] Gynecol Oncol. 2009 Jan;112(1):22-7 [18947860.001]
  • [Cites] Gynecol Oncol. 2009 Jan;112(1):28-34 [19010521.001]
  • [Cites] Gynecol Oncol. 2009 Feb;112(2):337-41 [19041126.001]
  • [Cites] Arch Pathol Lab Med. 2009 Nov;133(11):1775-81 [19886711.001]
  • [Cites] Int J Gynaecol Obstet. 2000 Aug;70(2):209-62 [11041682.001]
  • [Cites] Gynecol Oncol. 2003 Apr;89(1):16-21 [12694649.001]
  • [Cites] Int J Gynecol Cancer. 2004 May-Jun;14(3):399-422 [15228413.001]
  • [Cites] Major Probl Clin Surg. 1977;22:1-342 [839860.001]
  • [Cites] Surg Gynecol Obstet. 1991 Dec;173(6):454-60 [1948602.001]
  • [Cites] J Am Coll Surg. 1998 Nov;187(5):487-93 [9809564.001]
  • (PMID = 20662792.001).
  • [ISSN] 1477-2574
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3028582
  •  go-up   go-down


8. Homayounfar K, Gunawan B, Cameron S, Haller F, Baumhoer D, Uecker S, Sander B, Ramadori G, Lorf T, Füzesi L: Pattern of chromosomal aberrations in primary liver cancers identified by comparative genomic hybridization. Hum Pathol; 2009 Jun;40(6):834-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pattern of chromosomal aberrations in primary liver cancers identified by comparative genomic hybridization.
  • Seventy-eight cases of primary liver cancer with available median follow-up of 16.5 months, including 49 hepatocellular carcinomas, 22 cholangiocarcinomas, and 7 combined hepatocellular-cholangiocarcinomas, were examined by comparative genomic hybridization.
  • [MeSH-major] Chromosome Aberrations. Liver Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Hepatocellular / genetics. Carcinoma, Hepatocellular / pathology. Cholangiocarcinoma / genetics. Cholangiocarcinoma / pathology. Comparative Genomic Hybridization. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19200581.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Lee HL, Liu YY, Yeh CN, Chiang KC, Chen TC, Jan YY: Primary squamous cell carcinoma of the liver: a successful surgically treated case. World J Gastroenterol; 2006 Sep 7;12(33):5419-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary squamous cell carcinoma of the liver: a successful surgically treated case.
  • Primary squamous cell carcinoma (SCC) of the liver is rare.
  • Primary SCC of the liver has been reported to be associated with hepatic teratoma, hepatic cyst, or hepatolithiasis.
  • Complete remission of poorly differentiated SCC of the liver could be achieved by systemic chemotherapy followed by surgery or remarkably respond to hepatic arterial injection of low dose chemotherapeutic drugs.
  • Here we report the first case of primary SCC of the liver presenting as a solid tumor and receiving successful hepatic resection with 9-mo disease free survival.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / surgery. Liver Neoplasms / diagnosis. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Disease-Free Survival. Humans. Liver / pathology. Liver / ultrasonography. Male. Remission Induction. Treatment Outcome. Ultrasonography


10. Ye YJ, Wang S, Wu J, Shen ZL, Yin MJ, Yang XD, Jiang KW, Zhou J: [Clinicopathological analysis of synchronous hepatic metastases from colorectal cancer]. Zhonghua Wei Chang Wai Ke Za Zhi; 2008 May;11(3):208-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathological analysis of synchronous hepatic metastases from colorectal cancer].
  • OBJECTIVE: To screen the clinicopathological factors of synchronous hepatic metastases from colorectal cancer for early diagnosis and therapy.
  • METHODS: Clinicopathological data of 367 cases with colorectal cancer from Jan.
  • RESULTS: Out of 367 colorectal cancer cases, there were 56 cases with synchronous hepatic metastases from colorectal cancer, accounting for 15.3%.
  • The primary tumor located in the right colon resulted in more right lobe hepatic metastases than those in the left lobe.
  • CONCLUSION: Peritoneal or pelvic metastases, bowel obstruction, age and serum CEA level are associated with synchronous hepatic metastases from colorectal cancer.
  • [MeSH-major] Colorectal Neoplasms / pathology. Liver Neoplasms / pathology. Liver Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Young Adult


11. Ji SP, Li Q, Dong H: Therapy and prognostic features of primary clear cell carcinoma of the liver. World J Gastroenterol; 2010 Feb 14;16(6):764-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy and prognostic features of primary clear cell carcinoma of the liver.
  • AIM: To clarify the therapeutic strategies and prognosis factors of primary clear cell carcinoma of the liver (PCCCL).
  • The Kaplan-Meier method showed that capsule formation, preoperative liver function, hepatitis C virus infection, large vascular invasion and multiple tumor occurrences were related to disease-free survival.
  • Cox regression analysis showed that the clear cell ratio, capsule formation, preoperative liver function and large vascular invasion were independent risk factors for overall survival.
  • Clear cell ratio, capsule formation, preoperative liver function, and vascular invasion were independent risk factors for prognosis.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / surgery. Leucovorin / therapeutic use. Liver Neoplasms / drug therapy. Liver Neoplasms / surgery. Tegafur / therapeutic use
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / therapeutic use. Combined Modality Therapy. Female. Hepatectomy. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):177-82 [10680884.001]
  • [Cites] World J Gastroenterol. 2008 Mar 21;14(11):1652-6 [18350595.001]
  • [Cites] Histopathology. 2001 Mar;38(3):225-31 [11260303.001]
  • [Cites] Kaohsiung J Med Sci. 2004 Feb;20(2):78-82 [15481555.001]
  • [Cites] Cancer. 1979 Nov;44(5):1677-83 [227575.001]
  • [Cites] Pathologica. 1994 Jun;86(3):307-10 [7808805.001]
  • [Cites] Pathol Int. 1996 Jul;46(7):503-9 [8870006.001]
  • [Cites] Dig Dis Sci. 1998 Jan;43(1):33-8 [9508531.001]
  • [Cites] Oncogene. 1999 Jan 7;18(1):181-7 [9926933.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2005;12(2):155-8 [15868082.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2005 May;4(2):306-7 [15908336.001]
  • [Cites] World J Surg. 2006 Mar;30(3):439-45 [16479331.001]
  • [Cites] Hepatogastroenterology. 2006 Jan-Feb;53(67):128-32 [16506391.001]
  • [Cites] Oncogene. 2006 Jun 26;25(27):3866-84 [16799628.001]
  • [Cites] World J Surg. 2007 Jun;31(6):1243-8 [17440771.001]
  • [Cites] World J Gastroenterol. 2008 Jan 7;14(1):129-31 [18176975.001]
  • [Cites] Liver Int. 2008 Feb;28(2):175-88 [18251977.001]
  • [Cites] Mod Pathol. 2000 Aug;13(8):874-81 [10955454.001]
  • (PMID = 20135727.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 1548R74NSZ / Tegafur; Q573I9DVLP / Leucovorin
  • [Other-IDs] NLM/ PMC2817067
  •  go-up   go-down


12. Wong DW, Lupton SC, Bhatt L, Gross L, Tanière P, Peake DR, Spooner D, Geh JI: Use of imatinib mesylate in gastrointestinal stromal tumours: Pan-Birmingham Cancer Network experience. Clin Oncol (R Coll Radiol); 2008 Sep;20(7):517-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of imatinib mesylate in gastrointestinal stromal tumours: Pan-Birmingham Cancer Network experience.
  • MATERIALS AND METHODS: A retrospective audit of the use of imatinib mesylate in GISTs within the Pan-Birmingham Cancer Network was carried out.
  • RESULTS: The most common primary tumour sites were small intestine (19 [49%]) and stomach (12 [31%]).
  • Common sites of metastases were liver (19 [49%]) and peritoneum (12 [31%]).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Algorithms. Benzamides. Female. Humans. Imatinib Mesylate. Male. Middle Aged. Retrospective Studies. Survival Analysis

  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18514495.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


13. Morshed K, Szymański M, Siwiec H, Gołabek W: Laryngeal cancer in farmers from Lublin region of Poland. Ann Agric Environ Med; 2008;15(1):13-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laryngeal cancer in farmers from Lublin region of Poland.
  • The group included 148 patients with primary laryngeal squamous cell carcinoma (LSCC) diagnosed and treated in our institution in the years 1999-2002.
  • Nearly statistical significance was observed for the N stage (p=0.06) and for primary localisation of the tumour (p=0.05).
  • Distant metastases were observed in 7 (8.3%) of 84 farmers with LSCC, 6 to the lungs and one to the liver.
  • Farmers with larynx cancer had different presentation pattern than other profession patients.
  • The incidence of glottic cancer and well differentiated cancer was higher in farmers than in other professions.
  • The prevalence of larynx cancer in women was significantly lower among farmers than in other professions.
  • [MeSH-minor] Adult. Age Factors. Aged. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Poland / epidemiology. Risk Factors. Sex Factors

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • MedlinePlus Health Information. consumer health - Farm Health and Safety.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18581974.001).
  • [ISSN] 1232-1966
  • [Journal-full-title] Annals of agricultural and environmental medicine : AAEM
  • [ISO-abbreviation] Ann Agric Environ Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  •  go-up   go-down


1
Advertisement
4. Stîngu C, Mitulescu G, Ungureanu C, Popescu I: [Soft tissue reconstruction after total pelvic exenteration]. Chirurgia (Bucur); 2007 Jul-Aug;102(4):389-99
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During 2000-2006, in General Surgery and Liver Transplantation Fundeni, 73 patients with advanced pelvic cancer and invasive recurrences were operated.
  • We found that complications related to total pelvic exenteration dramatically decreased and primary healing of the perineal wound was superior, facts that correlate with the literature data.
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Omentum / transplantation. Pelvic Neoplasms / surgery. Pelvis / surgery. Quality of Life. Rectus Abdominis / transplantation. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17966934.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


15. Kianmanesh R, Scaringi S, Sabate JM, Castel B, Pons-Kerjean N, Coffin B, Hay JM, Flamant Y, Msika S: Iterative cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis of colorectal origin with or without liver metastases. Ann Surg; 2007 Apr;245(4):597-603
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Iterative cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis of colorectal origin with or without liver metastases.
  • INTRODUCTION: The aim of this study was to evaluate the results of an aggressive strategy in patients presenting peritoneal carcinomatosis (PC) from colorectal cancer with or without liver metastases (LMs) treated with cytoreductive surgery (CS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
  • The main endpoints were morbidity, mortality, completeness of cancer resection (CCR), and actuarial survival rates.
  • Three patients had prior to CS + HIPEC, 10 had concomitant minor liver resection, and 3 had differed liver resections (2 right hepatectomies) 2 months after CS + HIPEC.
  • The survival rates were not significantly different between patients who had CS + HIPEC for PC alone (including the primary resection) versus those who had associated LMs resection (median survival, 35.3 versus 36.0 months, P = 0.73).
  • CONCLUSION: Iterative CS + HIPEC is an effective treatment in PC from colorectal cancer.
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Hyperthermia, Induced. Infusions, Parenteral. Liver Neoplasms / secondary. Male. Middle Aged. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2005 Dec;32(6 Suppl 9):S118-22 [16399448.001]
  • [Cites] N Engl J Med. 2006 Jan 5;354(1):34-43 [16394300.001]
  • [Cites] Gastroenterol Clin Biol. 2005 Oct;29(10):1010-3 [16435508.001]
  • [Cites] J Gastrointest Surg. 2006 Feb;10(2):240-8 [16455457.001]
  • [Cites] Eur J Surg Oncol. 2006 Aug;32(6):632-6 [16621428.001]
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):790-6 [10622509.001]
  • [Cites] Cancer. 2000 Jan 15;88(2):358-63 [10640968.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):71-6 [11443611.001]
  • [Cites] Ann Surg. 2001 Aug;234(2):198-205 [11505065.001]
  • [Cites] Oncology. 2002;63(4):346-52 [12417789.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):799-806 [12610177.001]
  • [Cites] J Am Coll Surg. 2003 Jul;197(1):164-70 [12831938.001]
  • [Cites] Scand J Surg. 2003;92(2):178-9 [12841562.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3737-43 [14551293.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Jul;12(3):531-41 [14567016.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Jul;12(3):543-59 [14567017.001]
  • [Cites] Ann Surg Oncol. 2004 Feb;11(2):178-86 [14761921.001]
  • [Cites] Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):165-82 [15000156.001]
  • [Cites] Br J Surg. 2004 Apr;91(4):455-6 [15048746.001]
  • [Cites] Ann Surg Oncol. 2004 May;11(5):518-21 [15123461.001]
  • [Cites] Br J Surg. 2004 Jun;91(6):747-54 [15164446.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):818-25; discussion 825-7 [15166961.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):278-85 [15273552.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3284-92 [15310771.001]
  • [Cites] Eur J Surg Oncol. 2004 Oct;30(8):864-8 [15336733.001]
  • [Cites] Surgery. 1993 Jun;113(6):631-6 [8506520.001]
  • [Cites] Ann Surg. 1995 Feb;221(2):124-32 [7857141.001]
  • [Cites] World J Surg. 1995 Mar-Apr;19(2):235-40 [7754629.001]
  • [Cites] Cancer. 1996 Jun 15;77(12):2622-9 [8640714.001]
  • [Cites] Anticancer Res. 1999 May-Jun;19(3B):2317-21 [10472351.001]
  • [Cites] Bull Cancer. 2004 May;91(5):E113-32 [15568226.001]
  • [Cites] Curr Opin Obstet Gynecol. 2005 Feb;17(1):83-6 [15711417.001]
  • [Cites] Cancer Invest. 2005;23(2):155-72 [15813509.001]
  • [Cites] Ann Surg Oncol. 2005 Jan;12(1):65-71 [15827780.001]
  • [Cites] Curr Opin Oncol. 2005 Jul;17(4):397-9 [15933477.001]
  • [Cites] Tech Coloproctol. 2005 Jul;9(2):95-103 [16007367.001]
  • [Cites] Ann Surg. 2006 Feb;243(2):212-22 [16432354.001]
  • (PMID = 17414609.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1877034
  •  go-up   go-down


16. Ercolani G, Vetrone G, Grazi GL, Cescon M, Di Gioia P, Ravaioli M, Del Gaudio M, Tuci F, Zanello M, Cucchetti A, D Pinna A: The role of liver surgery in the treatment of non-colorectal non-neuroendocrine metastases (NCRNNE). Analysis of 134 resected patients. Minerva Chir; 2009 Dec;64(6):551-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of liver surgery in the treatment of non-colorectal non-neuroendocrine metastases (NCRNNE). Analysis of 134 resected patients.
  • AIM: The aim of this study was to evaluate the role of surgery in the treatment of non-colorectal, non-neuroendocrine (NCRNNE) liver metastases.
  • METHODS: One hundred and thirty-four patients undergoing curative liver resection for NCRNNE liver metastases were retrospectively analyzed.
  • The following prognostic factors were analyzed: age (cut-off 50 year old), single vs. multiple nodules, diameter (cut-off 5 cm), disease-free interval less vs. more than one year, type of primary tumor, blood transfusion, major hepatectomy vs. minor hepatectomy.
  • Survival of patients undergoing liver resection for metastatic colorectal cancer was also analyzed to compare the results with the study population.
  • Diameter, disease-free interval and metastases from gastrointestinal cancers were independently related to the survival at the multivariate analysis.
  • Patients with liver metastases from gastrointestinal primary tumors were those with a worse survival (25% and 19% at 3 and 5 years, respectively).
  • CONCLUSIONS: Surgery is an effective treatment for patients with NCRNNE liver metastases, providing satisfactory long-term outcomes with acceptable morbidity and mortality, in particular when excluding patients with gastro-intestinal metastases.
  • [MeSH-major] Hepatectomy. Liver Neoplasms / secondary. Liver Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20029352.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


17. Yuan SF, Li KZ, Wang L, Dou KF, Yan Z, Han W, Zhang YQ: Expression of MUC1 and its significance in hepatocellular and cholangiocarcinoma tissue. World J Gastroenterol; 2005 Aug 14;11(30):4661-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To investigate the relation between MUC1 expression, distribution, and prognosis in hepatocellular and cholangiocarcinoma (HCC and CC) and cirrhotic liver tissues, and their significance in HCC and CC diagnosis.
  • METHODS: Expression and distribution of MUC1 were examined by immunohistochemical assay with anti-MUC1 mAb in 59 samples of HCC and 37 samples of CC, 20 samples of cirrhotic liver tissues, and 10 samples of normal liver tissues, seeking possible associations between MUC1 positive expression, distribution in HCC and CC (primary liver cancer, PLC) cases and the studied clinical data.
  • Only 4 in the 20 cirrhotic liver tissues were found to be weak positive, while no expression of MUC1 was detected in normal liver tissues.
  • Apparently, the high expression rate of MUC1 in PLC tissues was statistically significant in comparison to that in cirrhotic and normal liver tissues.
  • The expressed MUC1 protein, stained in dark brownish or brownish-yellow particles, chiefly localized on the cancer cell membranes or in cytoplasm.
  • CONCLUSION: Expression and localization of MUC1 proteins in primary liver carcinomas (PLCs) may act as prognostic markers, and MUC1 molecules might be helpful in differential diagnosis.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Cholangiocarcinoma / metabolism. Liver Neoplasms / metabolism. Mucin-1 / metabolism
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Female. Humans. Liver Cirrhosis / metabolism. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16094706.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Mucin-1
  • [Other-IDs] NLM/ PMC4615407
  •  go-up   go-down


18. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crinò L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M, Masi G, Gruppo Oncologico Nord Ovest: Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol; 2007 May 1;25(13):1670-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.
  • METHODS: Selection criteria included unresectable metastatic colorectal cancer, age 18 to 75 years, and no prior chemotherapy for advanced disease.
  • The primary end point was response rate (RR).
  • The R0 secondary resection rate of metastases was greater in the FOLFOXIRI arm (6% v 15%; P = .033, among all 244 patients; and 12% v 36%; P = .017 among patients with liver metastases only).
  • CONCLUSION: The FOLFOXIRI regimen improves RR, PFS, and OS compared with FOLFIRI, with an increased, but manageable, toxicity in patients with metastatic colorectal cancer with favorable prognostic characteristics.
  • [MeSH-minor] Adult. Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Female. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Male. Middle Aged. Neoplasm Metastasis. Organoplatinum Compounds / administration & dosage. Quality of Life. Recurrence. Survival Analysis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17470860.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


19. Estrada-Sánchez G, Ochoa-Carrillo FJ, Altamirano-Ley J: [(18)FDG PET/CT imaging in primary breast lymphoma and breast cancer]. Cir Cir; 2008 Jul-Aug;76(4):279-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [(18)FDG PET/CT imaging in primary breast lymphoma and breast cancer].
  • BACKGROUND: Of women between 15 and 29 years of age, 13.6% will die from breast cancer.
  • For women between 30 and 64 years of age, 19% will die from breast cancer.
  • METHODS: We studied 1728 oncological patients and 295 patients were included, 293 with breast cancer (17%) and two patients with primary breast lymphoma (0.1%).
  • SUVmax for the primary tumor was 4.2 +/- 2.6 SD.
  • Mean SUVmax for patients with primary breast lymphoma were 3.2 and 1.4.
  • Sites of metastases were lymph nodes in the neck (4.4% SUVmax 2.7), internal mammary lymph nodes (5% SUVmax 5.3), mediastinum (8.3% SUVmax 5.0), retroperitoneal (6 % SUVmax 5.4), ipsilateral axilla (94% SUVmax 4.5), contralateral axilla (4.4% SUVmax 2.8), pectoral muscle (10.2% SUVmax 2.6), pleura (4.4% SUVmax 3.9), lung (32.3% SUVmax 2.9), liver (19.1% SUVmax 4.5), bone (36.7%), adrenal gland (4.4% SUVmax 2.4), brain (4.4%), spleen and contralateral breast, one case each.
  • The incidence of a second primary was 4.7%, 2.1% ovarian, 1.4% lung, 0.3% lymphoma, 0.3% endometrium, 0.3% pancreas and 0.3% thyroid.
  • CONCLUSIONS: Mean SUVmax for the primary tumor was similar to that reported in the literature.
  • [MeSH-minor] Adult. Bone Neoplasms / radiography. Bone Neoplasms / radionuclide imaging. Bone Neoplasms / secondary. Brain Neoplasms / radiography. Brain Neoplasms / radionuclide imaging. Brain Neoplasms / secondary. Breast Neoplasms, Male / radiography. Breast Neoplasms, Male / radionuclide imaging. Cost-Benefit Analysis. Female. Fluorine Radioisotopes. Fluorodeoxyglucose F18. Humans. Hyperplasia. Lymphatic Metastasis / radiography. Lymphatic Metastasis / radionuclide imaging. Lymphoma, Non-Hodgkin / radiography. Lymphoma, Non-Hodgkin / radionuclide imaging. Male. Mammography. Neoplasms, Multiple Primary / radiography. Neoplasms, Multiple Primary / radionuclide imaging. Radiopharmaceuticals. Retrospective Studies. Sensitivity and Specificity. Thymus Gland / pathology. Thymus Gland / radionuclide imaging

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18778536.001).
  • [ISSN] 0009-7411
  • [Journal-full-title] Cirugía y cirujanos
  • [ISO-abbreviation] Cir Cir
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Fluorine Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


20. Ahmad A, Chen SL, Bilchik AJ: Role of repeated hepatectomy in the multimodal treatment of hepatic colorectal metastases. Arch Surg; 2007 Jun;142(6):526-31; discussion 531-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HYPOTHESIS: Multimodal treatment consisting of repeated hepatectomy and adjuvant systemic chemotherapy for liver-confined recurrence of colorectal cancer can yield long-term survival comparable with that associated with primary hepatectomy.
  • SETTING: A prospective database at a tertiary referral cancer center.
  • PATIENTS: Review of 274 consecutive liver resections identified 64 patients who underwent resection of hepatic colorectal metastases without ablation followed by adjuvant irinotecan hydrochloride- or oxaliplatin-based systemic chemotherapy.
  • MAIN OUTCOME MEASURES: Median and 5-year overall and disease-free survival after primary and repeated hepatectomy.
  • Multivariate analysis showed that less than 1 year between colectomy and liver resection (P = .001), more than 3 metastases (P = .001), no repeated hepatectomy (P = .01), and lymph node-positive primary colon cancer (P = .02) were independently predictive of worse survival.
  • Of 28 patients (44%) with liver-confined recurrence, 19 (30%) underwent repeated hepatectomy; at median follow-up of 38 months, median and 5-year overall survival after repeated hepatectomy were 48 months and 44%, respectively.
  • In patients with recurrence, median and 5-year overall survival measured from primary hepatectomy were 70 months and 73%, respectively, with repeated hepatectomy vs 43 months and 43%, respectively, without repeated hepatectomy (P = .03).
  • CONCLUSION: Multimodal treatment of recurrent colorectal cancer confined to the liver should begin with consideration of repeated hepatectomy.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Camptothecin / analogs & derivatives. Colorectal Neoplasms / pathology. Hepatectomy. Liver Neoplasms / therapy. Neoplasm Recurrence, Local / therapy. Organoplatinum Compounds / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Reoperation. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17576888.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


21. Fishman M, Hunter TB, Soliman H, Thompson P, Dunn M, Smilee R, Farmelo MJ, Noyes DR, Mahany JJ, Lee JH, Cantor A, Messina J, Seigne J, Pow-Sang J, Janssen W, Antonia SJ: Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma. J Immunother; 2008 Jan;31(1):72-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vaccination consisted of autologous cells cultured from primary tumor or resected metastasis, transduced to express B7.1 surface molecule and then irradiated.
  • [MeSH-major] Antigens, CD80 / immunology. Cancer Vaccines / therapeutic use. Carcinoma, Renal Cell / therapy. Interleukin-2 / therapeutic use. Kidney Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Interferon-gamma / metabolism. Leukocytes, Mononuclear / drug effects. Leukocytes, Mononuclear / immunology. Leukocytes, Mononuclear / metabolism. Liver / drug effects. Liver / immunology. Liver / pathology. Male. Middle Aged. Neoplasm Staging. Skin / drug effects. Skin / immunology. Skin / pathology. Survival Analysis. Transfection. Treatment Outcome. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18157014.001).
  • [ISSN] 1524-9557
  • [Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)
  • [ISO-abbreviation] J. Immunother.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R03 CA 82059-01
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD80; 0 / Cancer Vaccines; 0 / Interleukin-2; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


22. Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ, Weeks JC, Sigurdson ER, Herndon JE 2nd, Zhang C, Mayer RJ: Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol; 2006 Mar 20;24(9):1395-403
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481).
  • PURPOSE: Hepatic metastases derive most of their blood supply from the hepatic artery; therefore, for patients with hepatic metastases from colorectal cancer, hepatic arterial infusion (HAI) of chemotherapy may improve outcome.
  • The primary end point was survival; secondary end points were response, recurrence, toxicity, quality of life, cost, and the influence of molecular markers.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / pathology. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor. Disease Progression. Female. Fluorouracil / administration & dosage. Hepatic Artery. Humans. Infusions, Intra-Arterial. Injections, Intravenous. Leucovorin / administration & dosage. Male. Middle Aged. Quality of Life. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2008 Oct 1;26(28):4528-9 [18824703.001]
  • (PMID = 16505413.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA03927; United States / NCI NIH HHS / CA / CA04326; United States / NCI NIH HHS / CA / CA07968; United States / NCI NIH HHS / CA / CA12046; United States / NCI NIH HHS / CA / CA12449; United States / NCI NIH HHS / CA / CA16450; United States / NCI NIH HHS / CA / CA21060; United States / NCI NIH HHS / CA / CA23318; United States / NCI NIH HHS / CA / CA27525; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA32291; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA60138; United States / NCI NIH HHS / CA / CA77651
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


23. Hurlstone DP, Sanders DS, Atkinson R, Hunter MD, McAlindon ME, Lobo AJ, Cross SS, Thomson M: Endoscopic mucosal resection for flat neoplasia in chronic ulcerative colitis: can we change the endoscopic management paradigm? Gut; 2007 Jun;56(6):838-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Prospective clinical, pathological and outcome data of patients with colitis-associated Paris class 0-II and Paris class I ALM treated with EMR (primary end points being colorectal cancer development, resection efficacy, metachronous lesion rates and post-resection recurrence rates) were compared with those of sporadic controls.
  • 170 ALMs, 18 dysplasia-associated lesion masses (DALMs) and 16 cancers were diagnosed.
  • 1675 controls were included from our prospective database of patients without CUC who had undergone EMR for sporadic Paris class 0-II and snare polypectomy of Paris type I lesions from 1998 onwards, and were considered to be at moderate to high lifetime risk of colorectal cancer.
  • No statistically significant differences were observed between the CUC study group and controls with respect to age, sex, median number of colonoscopies per patient, median follow-up duration, post-resection complications, median lesional diameter or interval cancer rates.
  • [MeSH-minor] Adult. Aged. Chronic Disease. Female. Follow-Up Studies. Humans. Male. Middle Aged. Precancerous Conditions / etiology. Precancerous Conditions / pathology. Precancerous Conditions / surgery. Prospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Ulcerative Colitis.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 1999 Dec;117(6):1288-94; discussion 1488-91 [10579969.001]
  • [Cites] Endoscopy. 2005 Dec;37(12):1186-92 [16329015.001]
  • [Cites] Int J Oncol. 2000 May;16(5):927-34 [10762628.001]
  • [Cites] Gut. 2000 Aug;47(2):251-5 [10896917.001]
  • [Cites] Am J Gastroenterol. 2000 Oct;95(10):2710-9 [11051339.001]
  • [Cites] Endoscopy. 2001 Apr;33(4):367-73 [11315901.001]
  • [Cites] Gastrointest Endosc. 2002 Mar;55(3):371-5 [11868011.001]
  • [Cites] Gastrointest Endosc. 2002 Mar;55(3):390-6 [11868015.001]
  • [Cites] Br J Surg. 2002 Mar;89(3):272-82 [11872049.001]
  • [Cites] Gastrointest Endosc. 2002 Sep;56(3):333-8 [12196768.001]
  • [Cites] Gastroenterology. 2003 Apr;124(4):880-8 [12671882.001]
  • [Cites] Endoscopy. 2003 Oct;35(10):845-9 [14551863.001]
  • [Cites] Am J Gastroenterol. 2003 Nov;98(11):2543-9 [14638361.001]
  • [Cites] Gastrointest Endosc. 2003 Dec;58(6 Suppl):S3-43 [14652541.001]
  • [Cites] Gut. 2004 Feb;53(2):256-60 [14724160.001]
  • [Cites] Gut. 2004 Feb;53(2):284-90 [14724165.001]
  • [Cites] Gastroenterology. 2004 Jan;126(1):376-8 [14753220.001]
  • [Cites] Gut. 2004 Mar;53(3):376-80 [14960519.001]
  • [Cites] Gastrointest Endosc. 2004 May;59(6):642-50 [15114306.001]
  • [Cites] Endoscopy. 2004 Jun;36(6):491-8 [15202044.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Jul;2(7):534-41 [15224277.001]
  • [Cites] Gut. 2004 Sep;53(9):1334-9 [15306595.001]
  • [Cites] Gut. 2004 Sep;53 Suppl 5:V1-16 [15306569.001]
  • [Cites] Gastroenterology. 2004 Sep;127(3):706-13 [15362025.001]
  • [Cites] Gastroenterology. 1981 Feb;80(2):366-74 [7450425.001]
  • [Cites] J Natl Cancer Inst. 1990 Nov 21;82(22):1769-72 [2231773.001]
  • [Cites] Gastroenterology. 1991 May;100(5 Pt 1):1241-8 [2013371.001]
  • [Cites] Gastroenterology. 1994 Oct;107(4):934-44 [7926483.001]
  • [Cites] Gut. 1994 Oct;35(10):1419-23 [7959198.001]
  • [Cites] Gastroenterology. 1997 Jan;112(1):24-8 [8978338.001]
  • [Cites] World J Surg. 1997 Sep;21(7):694-701 [9276699.001]
  • [Cites] Gastroenterology. 1999 Dec;117(6):1295-300 [10579970.001]
  • (PMID = 17135310.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1954845
  •  go-up   go-down


24. Vernez M, Hutter P, Monnerat C, Halkic N, Gugerli O, Bouzourene H: A case of Muir-Torre syndrome associated with mucinous hepatic cholangiocarcinoma and a novel germline mutation of the MSH2 gene. Fam Cancer; 2007;6(1):141-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Muir-Torre syndrome (MTS) is a rare cancer-predisposing syndrome that is autosomal dominantly inherited and characterized by the development of sebaceous skin lesions (adenomas, epitheliomas, basaliomas and carcinomas).
  • These lesions are typically associated with tumors that belong to the spectrum of hereditary nonpolyposis colorectal cancer (HNPCC) (i.e., tumors of the colorectum, endometrium, stomach or ovary).
  • [MeSH-major] Cholangiocarcinoma / genetics. Cholangiocarcinoma / secondary. Germ-Line Mutation. Liver Neoplasms / genetics. MutS Homolog 2 Protein / deficiency. Neoplasms, Multiple Primary / genetics. Neoplastic Syndromes, Hereditary / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / surgery. Adenoma / genetics. Adenoma / surgery. Adult. Brain Neoplasms / genetics. Brain Neoplasms / secondary. Brain Neoplasms / surgery. Carcinoma / genetics. Carcinoma / surgery. Colorectal Neoplasms, Hereditary Nonpolyposis / genetics. Colorectal Neoplasms, Hereditary Nonpolyposis / surgery. DNA Mutational Analysis. DNA Probes. DNA-Binding Proteins. Endometrial Neoplasms / surgery. Female. Humans. Microsatellite Instability. Mutation, Missense. Polyps / surgery. Proline / genetics. Sebaceous Gland Neoplasms / genetics. Sebaceous Gland Neoplasms / surgery. Serine / genetics. Syndrome

  • Genetic Alliance. consumer health - Keratoacanthoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-PROLINE .
  • Hazardous Substances Data Bank. L-SERINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1967 Mar;54(3):191-5 [6020987.001]
  • [Cites] Arch Dermatol. 1968 Nov;98(5):549-51 [5684233.001]
  • [Cites] J Med Genet. 2004 Jul;41(7):567-72 [15235030.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):896-9 [11221877.001]
  • [Cites] Fam Cancer. 2005;4(3):245-8 [16136385.001]
  • [Cites] Cancer Res. 1994 Mar 1;54(5):1159-63 [8118799.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Clin Genet. 2005 Nov;68(5):442-7 [16207212.001]
  • [Cites] Scand J Gastroenterol. 2005 Apr;40(4):455-9 [16028441.001]
  • [Cites] Cancer. 1992 Mar 1;69(5):1112-4 [1310886.001]
  • [Cites] J Am Acad Dermatol. 1999 Nov;41(5 Pt 1):681-6 [10534628.001]
  • [Cites] EMBO J. 1998 May 1;17 (9):2677-86 [9564049.001]
  • [Cites] Lancet. 2005 Oct 8;366(9493):1303-14 [16214602.001]
  • [Cites] J Am Acad Dermatol. 1995 Jul;33(1):90-104 [7601953.001]
  • (PMID = 17051350.001).
  • [ISSN] 1389-9600
  • [Journal-full-title] Familial cancer
  • [ISO-abbreviation] Fam. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA Probes; 0 / DNA-Binding Proteins; 452VLY9402 / Serine; 9DLQ4CIU6V / Proline; EC 3.6.1.3 / MutS Homolog 2 Protein
  •  go-up   go-down


25. Stemmler HJ, Harbeck N, Gröll de Rivera I, Vehling Kaiser U, Rauthe G, Abenhardt W, Artmann A, Sommer H, Meerpohl HG, Kiechle M, Heinemann V: Prospective multicenter randomized phase III study of weekly versus standard docetaxel plus doxorubicin (D4) for first-line treatment of metastatic breast cancer. Oncology; 2010;79(3-4):204-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective multicenter randomized phase III study of weekly versus standard docetaxel plus doxorubicin (D4) for first-line treatment of metastatic breast cancer.
  • RESULTS: Since interim analysis showed failure to reach a significant difference for the primary endpoint (hematotoxicity, i.e. leukopenia), the study was closed according to the study protocol (85 of 242 patients).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Doxorubicin / administration & dosage. Female. Humans. Lymphatic Metastasis. Middle Aged. Prospective Studies. Survival Rate. Taxoids / administration & dosage. Treatment Outcome. Young Adult


26. van der Pool AE, Lalmahomed ZS, Ozbay Y, de Wilt JH, Eggermont AM, Jzermans JN, Verhoef C: 'Staged' liver resection in synchronous and metachronous colorectal hepatic metastases: differences in clinicopathological features and outcome. Colorectal Dis; 2010 Oct;12(10 Online):e229-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 'Staged' liver resection in synchronous and metachronous colorectal hepatic metastases: differences in clinicopathological features and outcome.
  • AIM: Approximately 25% of the patients with colorectal cancer already have liver metastases at diagnosis and another 30% will develop them subsequently.
  • The features and prognosis of patients with synchronous and metachronus colorectal liver metastases, treated with primary resection first followed by partial liver resection were analysed.
  • METHOD: Curative staged resection of liver metastases was performed in 272 consecutive patients.
  • Demographics, characteristics of the primary tumour and metastatic tumours, surgery-related data and outcome were analysed.
  • More patients in the synchronous group had an advanced primary tumour (T3/T4 and/or node positivity), more than three liver metastases and bilobar distribution.
  • CONCLUSION: Although patients with synchronous colorectal liver metastases may have poorer biological features, there was no difference in 5-year disease-free and overall survival compared with patients with metachronous metastases.
  • [MeSH-major] Carcinoma / secondary. Carcinoma / surgery. Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery. Liver Neoplasms / secondary. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Hepatectomy. Humans. Male. Middle Aged. Neoadjuvant Therapy. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Colorectal Disease © 2010 The Association of Coloproctology of Great Britain and Ireland.
  • (PMID = 19912286.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


27. Zhang F, Wang X, Li X, Kong L, Sun B, Li G, Qian X, Chen F, Wang K, Lu S, Pu L, Lu L: Emergency adult living donor right lobe liver transplantation for fulminant hepatic failure. Front Med China; 2007 Jul;1(3):282-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emergency adult living donor right lobe liver transplantation for fulminant hepatic failure.
  • Fulminant hepatitis is fatal in most cases and timely liver transplantation is the only effective treatment.
  • This study evaluates the survival outcomes of patients who underwent living-donor liver transplantation (LDLT) using right lobe liver grafts for fulminant liver failure due to hepatitis B infection.
  • Nine cases of adult right lobe LDLT were performed in our department from September 2002 to August 2005 and the clinical and following-up data were reviewed.
  • The model for end-stage liver disease (MELD) score of these patients ranged from 16 to 42.
  • No primary failure of vascular or biliary complications occurred.
  • Emergency adult living-donor liver transplantation is an effective treatment for fulminant hepatitis patients and is relatively safe for donors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chin Med J (Engl). 2006 Jun 20;119(12):1003-9 [16805984.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):141-8 [16708358.001]
  • [Cites] N Engl J Med. 2003 Feb 27;348(9):818-25 [12606737.001]
  • [Cites] Ann Surg. 2001 Sep;234(3):301-11; discussion 311-2 [11524583.001]
  • [Cites] Surgery. 2002 Jan;131(1 Suppl):S200-4 [11821811.001]
  • [Cites] Hepatology. 2001 Feb;33(2):464-70 [11172350.001]
  • [Cites] Transplantation. 1999 Jan 15;67(1):73-7 [9921799.001]
  • [Cites] Liver Transpl. 2000 Nov;6(6 Suppl 2):S64-5 [11084088.001]
  • [Cites] Liver Transpl Surg. 1999 May;5(3):161-5 [10226105.001]
  • [Cites] Transplantation. 2000 Jun 15;69(11):2410-5 [10868650.001]
  • [Cites] Surgery. 2006 Nov;140(5):824-8; discussion 829 [17084727.001]
  • [Cites] Liver Transpl. 2001 Oct;7(10):890-5 [11679988.001]
  • [Cites] Liver Transpl. 2000 Nov;6(6 Suppl 2):S66-72 [11084089.001]
  • [Cites] Zhonghua Gan Zang Bing Za Zhi. 2005 Dec;13(12):881-91 [16491521.001]
  • [Cites] Liver Transpl. 2000 Mar;6(2):163-9 [10719014.001]
  • [Cites] Clin Transplant. 2003 Feb;17(1):37-42 [12588320.001]
  • [Cites] Ann Surg. 2000 Jun;231(6):824-31 [10816625.001]
  • [Cites] Liver Transpl. 2006 Jul;12(7):1049-61 [16799946.001]
  • [Cites] Gastroenterology. 1984 Jun;86(6):1417-20 [6714570.001]
  • (PMID = 24573867.001).
  • [ISSN] 1673-7342
  • [Journal-full-title] Frontiers of medicine in China
  • [ISO-abbreviation] Front Med China
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


28. de Santibañes E, Fernandez D, Vaccaro C, Quintana GO, Bonadeo F, Pekolj J, Bonofiglio C, Molmenti E: Short-term and long-term outcomes after simultaneous resection of colorectal malignancies and synchronous liver metastases. World J Surg; 2010 Sep;34(9):2133-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short-term and long-term outcomes after simultaneous resection of colorectal malignancies and synchronous liver metastases.
  • BACKGROUND: We evaluated the simultaneous resection of colorectal malignancies and synchronous liver metastases.
  • In all, 185 (25%) of them underwent simultaneous resection of the hepatic lesions and the corresponding primary tumors.
  • CONCLUSIONS: The simultaneous resection of colorectal malignancies and synchronous liver metastases is safe, avoids an additional intervention, can be performed with low morbidity and mortality, and is associated with good oncologic outcomes.
  • [MeSH-major] Colectomy. Colorectal Neoplasms / surgery. Hepatectomy. Liver Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoembryonic Antigen / analysis. Female. Humans. Length of Stay. Male. Middle Aged. Patient Selection. Prognosis. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] World J Surg. 2011 Apr;35(4):926-7; author reply 928 [20981543.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):938-46 [9060531.001]
  • [Cites] Br J Surg. 1990 Nov;77(11):1241-6 [2253003.001]
  • [Cites] Ann Ital Chir. 1996 Nov-Dec;67(6):761-5 [9214268.001]
  • [Cites] J Am Coll Surg. 2003 Aug;197(2):233-41; discussion 241-2 [12892803.001]
  • [Cites] HPB Surg. 1993;6(3):199-203; discussion 203-4 [8387809.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):136-47 [10623704.001]
  • [Cites] Am J Surg. 1997 Jun;173(6):467-71 [9207156.001]
  • [Cites] J Am Coll Surg. 2002 Aug;195(2):196-202 [12168966.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Dis Colon Rectum. 2000 Oct;43(10 Suppl):S78-84 [11052482.001]
  • [Cites] Eur J Surg Oncol. 2007 Dec;33 Suppl 2:S35-41 [17981428.001]
  • [Cites] J Surg Oncol. 2001 Sep;78(1):17-21 [11519063.001]
  • [Cites] Br J Surg. 2007 Feb;94(2):129-31 [17256808.001]
  • [Cites] Int J Colorectal Dis. 2007 Oct;22(10):1269-76 [17318552.001]
  • [Cites] Ann Surg. 1997 Nov;226(5):582-6 [9389391.001]
  • [Cites] Br J Surg. 2006 Jul;93(7):872-8 [16671066.001]
  • [Cites] Radiology. 2001 Jan;218(1):55-60 [11152779.001]
  • [Cites] Lancet. 1998 Oct 31;352(9138):1407-12 [9807986.001]
  • [Cites] World J Surg. 1987 Aug;11(4):541-7 [3630198.001]
  • [Cites] J Am Coll Surg. 1999 Sep;189(3):291-9 [10472930.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1007-16 [18358928.001]
  • [Cites] Dis Colon Rectum. 2002 Apr;45(4):476-84 [12006929.001]
  • [Cites] Coll Antropol. 2000 Dec;24(2):381-90 [11216406.001]
  • [Cites] Surgery. 2004 Sep;136(3):650-9 [15349115.001]
  • [Cites] Eur J Surg Oncol. 1990 Aug;16(4):360-5 [2379594.001]
  • [Cites] Arch Surg. 2000 Apr;135(4):473-9; discussion 479-80 [10768715.001]
  • [Cites] Semin Oncol. 1991 Aug;18(4):399-406 [1650502.001]
  • [Cites] Arch Surg. 1997 Feb;132(2):115-9 [9041911.001]
  • [Cites] Dis Colon Rectum. 1996 Apr;39(4):429-34 [8878504.001]
  • [Cites] Dis Colon Rectum. 2004 Aug;47(8):1269-84 [15484340.001]
  • [Cites] J Surg Oncol. 2005 Nov 1;92(2):124-9 [16231370.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):195-201 [17080238.001]
  • [Cites] Ann Chir. 1996;50(7):507-12; discussion 13-6 [9035419.001]
  • [Cites] Am Surg. 1997 Jul;63(7):605-10 [9202534.001]
  • [Cites] Surgery. 1988 Mar;103(3):278-88 [3278402.001]
  • [Cites] Colorectal Dis. 2009 Jan;11(1):3-10 [18637099.001]
  • [Cites] Dis Colon Rectum. 2004 Aug;47(8):1310-6 [15484344.001]
  • [Cites] Ann Surg. 2004 Sep;240(3):438-47; discussion 447-50 [15319715.001]
  • [Cites] Br J Surg. 1999 Mar;86(3):332-7 [10201774.001]
  • [Cites] World J Surg. 1991 Jan-Feb;15(1):62-7 [1994607.001]
  • [Cites] Cancer. 1996 Apr 1;77(7):1254-62 [8608500.001]
  • [Cites] J Surg Oncol. 1998 Oct;69(2):88-93 [9808511.001]
  • [Cites] Am J Surg. 1999 Oct;178(4):282-7 [10587184.001]
  • [Cites] Eur J Surg Oncol. 2005 Jun;31(5):506-11 [15922887.001]
  • [Cites] Ann Surg Oncol. 2007 Mar;14(3):1143-50 [17200913.001]
  • [Cites] Br J Surg. 2003 Aug;90(8):956-62 [12905548.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):205-13 [15273542.001]
  • [Cites] Arch Surg. 2006 Oct;141(10):1006-12; discussion 1013 [17043279.001]
  • [Cites] J Clin Oncol. 2003 Jun 1;21(11):2059-69 [12775730.001]
  • [Cites] Radiology. 2002 Sep;224(3):748-56 [12202709.001]
  • [Cites] N Engl J Med. 1994 Apr 21;330(16):1136-42 [8133857.001]
  • [Cites] J Nucl Med. 2000 Jul;41(7):1177-89 [10914907.001]
  • [Cites] J Am Coll Surg. 1997 Apr;184(4):413-34 [9100690.001]
  • [Cites] Jpn J Clin Oncol. 2000 Jan;30(1):7-11 [10770561.001]
  • [Cites] Am J Surg. 1995 Feb;169(2):254-60 [7840389.001]
  • [Cites] Lancet. 2000 Mar 25;355(9209):1041-7 [10744089.001]
  • [Cites] Br J Surg. 1999 Feb;86(2):158-69 [10100781.001]
  • [Cites] Ann Surg. 2000 Apr;231(4):487-99 [10749608.001]
  • [Cites] J Gastrointest Surg. 2003 Jan;7(1):109-15; discussion 116-7 [12559192.001]
  • [Cites] World J Gastroenterol. 2003 Feb;9(2):193-200 [12532430.001]
  • [Cites] Dig Surg. 2008;25(6):430-5 [19212115.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):2938-47 [10944126.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21 [10493478.001]
  • [Cites] Br J Surg. 1991 Jul;78(7):797-801 [1873704.001]
  • [Cites] Surgery. 1991 Jul;110(1):13-29 [1866690.001]
  • (PMID = 20532766.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


29. Kang TW, Rhim H, Kim EY, Kim YS, Choi D, Lee WJ, Lim HK: Percutaneous radiofrequency ablation for the hepatocellular carcinoma abutting the diaphragm: assessment of safety and therapeutic efficacy. Korean J Radiol; 2009 Jan-Feb;10(1):34-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As well, the primary and secondary technique effectiveness rates in group A and group B were 90% versus 98% (p = 0.29) and 79% versus 91% (p = 0.25), respectively.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Catheter Ablation / adverse effects. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Burns / etiology. Diaphragm / injuries. Diaphragm / pathology. Female. Humans. Lung Injury / etiology. Male. Middle Aged. Shoulder Pain / etiology. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2000 Mar;214(3):761-8 [10715043.001]
  • [Cites] AJR Am J Roentgenol. 1999 Nov;173(5):1231-3 [10541094.001]
  • [Cites] Radiology. 2002 Mar;222(3):819-23 [11867807.001]
  • [Cites] Arch Surg. 2002 Apr;137(4):422-6; discussion 427 [11926946.001]
  • [Cites] Radiographics. 2002 Oct;22 Spec No:S103-16; discussion S116-8 [12376604.001]
  • [Cites] Radiographics. 2003 Jan-Feb;23(1):123-34; discussion 134-6 [12533647.001]
  • [Cites] Radiology. 2003 Feb;226(2):441-51 [12563138.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1253-62 [12599233.001]
  • [Cites] AJR Am J Roentgenol. 2003 Jun;180(6):1561-2 [12760919.001]
  • [Cites] AJR Am J Roentgenol. 2003 Sep;181(3):695-700 [12933462.001]
  • [Cites] Cardiovasc Intervent Radiol. 2003 May-Jun;26(3):302-4 [14562984.001]
  • [Cites] J Gastroenterol. 2003;38(10):977-81 [14614605.001]
  • [Cites] Radiographics. 2004 Jan-Feb;24(1):41-52 [14730035.001]
  • [Cites] AJR Am J Roentgenol. 2004 May;182(5):1224-6 [15100123.001]
  • [Cites] AJR Am J Roentgenol. 2004 Jul;183(1):197-200 [15208138.001]
  • [Cites] AJR Am J Roentgenol. 2004 Sep;183(3):583-8 [15333339.001]
  • [Cites] AJR Am J Roentgenol. 2004 Nov;183(5):1417-24 [15505314.001]
  • [Cites] J Neurophysiol. 1991 May;65(5):1042-54 [1869904.001]
  • [Cites] World J Surg. 1992 Jan-Feb;16(1):2-9 [1290261.001]
  • [Cites] AJR Am J Roentgenol. 1999 Jan;172(1):65-6 [9888741.001]
  • [Cites] J Burn Care Rehabil. 2005 May-Jun;26(3):207-27 [15879742.001]
  • [Cites] Radiology. 2005 Jun;235(3):728-39 [15845798.001]
  • [Cites] World J Gastroenterol. 2005 Oct 28;11(40):6395-401 [16419172.001]
  • [Cites] J Vasc Interv Radiol. 2006 Mar;17(3):541-7 [16567679.001]
  • [Cites] AJR Am J Roentgenol. 2006 May;186(5 Suppl):S269-74 [16632687.001]
  • [Cites] Hepatology. 2006 May;43(5):1101-8 [16628706.001]
  • [Cites] Radiology. 2007 Jun;243(3):877-84 [17517940.001]
  • [Cites] AJR Am J Roentgenol. 2008 Jan;190(1):91-8 [18094298.001]
  • [Cites] AJR Am J Roentgenol. 2008 Apr;190(4):1029-34 [18356451.001]
  • [Cites] Radiology. 2008 Aug;248(2):670-9 [18519740.001]
  • [Cites] Am J Gastroenterol. 2000 Sep;95(9):2401-3 [11007264.001]
  • (PMID = 19182501.001).
  • [ISSN] 1229-6929
  • [Journal-full-title] Korean journal of radiology
  • [ISO-abbreviation] Korean J Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2647171
  •  go-up   go-down


30. Shirakawa H, Kuronuma T, Nishimura Y, Hasebe T, Nakano M, Gotohda N, Takahashi S, Nakagohri T, Konishi M, Kobayashi N, Kinoshita T, Nakatsura T: Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. Int J Oncol; 2009 Mar;34(3):649-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer.
  • Primary liver cancers are classified into three types based on their morphology and cytogenetic characteristics hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and combined hepatocellular and cholangiocarcinoma (CHC).
  • It is often difficult to distinguish these liver tumors.
  • In order to separate these three types of liver cancers, we analyzed the GPC3 expression in 85 liver resection specimens, including 46 HCCs, 28 ICCs and 11 CHCs.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Carcinoma, Hepatocellular / metabolism. Cholangiocarcinoma / metabolism. Glypicans / biosynthesis. Liver Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bile Duct Neoplasms / metabolism. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / metabolism. Bile Ducts, Intrahepatic / pathology. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19212669.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPC3 protein, human; 0 / Glypicans
  •  go-up   go-down


31. Kosmidis PA, Kalofonos HP, Christodoulou C, Syrigos K, Makatsoris T, Skarlos D, Bakogiannis C, Nicolaides C, Bafaloukos D, Bamias A, Samantas E, Xiros N, Boukovinas I, Fountzilas G, Dimopoulos MA: Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group. Ann Oncol; 2008 Jan;19(1):115-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group.
  • BACKGROUND: This phase III study was designed to compare the combination paclitaxel (Taxol)-gemcitabine (PG) versus carboplatin-gemcitabine (CG) in patients with advanced inoperable non-small-cell lung cancer.
  • Primary end point was overall survival (OS).

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CIMETIDINE .
  • Hazardous Substances Data Bank. DIPHENHYDRAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17938425.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 4AF302ESOS / Ondansetron; 7S5I7G3JQL / Dexamethasone; 80061L1WGD / Cimetidine; 8GTS82S83M / Diphenhydramine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


32. Waas ET, Wobbes T, Ruers T, Lomme RM, Hendriks T: Circulating gelatinases and tissue inhibitor of metalloproteinase-1 in colorectal cancer metastatic liver disease. Eur J Surg Oncol; 2006 Sep;32(7):756-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating gelatinases and tissue inhibitor of metalloproteinase-1 in colorectal cancer metastatic liver disease.
  • AIMS: The degradation of the extracellular matrix is intrinsic to the invasion and progression of cancer.
  • The study aims to investigate if plasma MMP-2, -9 and tissue inhibitor of metalloproteinase-1 (TIMP-1) can be useful markers in the diagnosis and prognosis of colorectal cancer (CRC) metastatic liver disease.
  • METHODS: Fifty-seven patients undergoing liver metastasis operation were followed prospectively.
  • ProMMP-2, -9 and TIMP-1 plasma levels were determined by zymography and ELISA, before and after the resection of liver metastases.
  • Data were compared with those of healthy controls (n=51) and primary CRC patients (n=94).
  • RESULTS: Plasma proMMP-2 levels were lower (P<0.001), and TIMP-1 levels higher (P<0.001) in CRC metastatic liver disease than in healthy controls.
  • If compared to those in primary CRC patients, no differences were found.
  • CONCLUSION: The preoperative plasma proMMP-2, -9 and TIMP-1 levels have no potential value as diagnostic or prognostic markers in CRC liver metastatic disease.
  • [MeSH-major] Colorectal Neoplasms / blood. Colorectal Neoplasms / pathology. Liver Neoplasms / blood. Liver Neoplasms / secondary. Matrix Metalloproteinase 2 / blood. Matrix Metalloproteinase 9 / blood. Tissue Inhibitor of Metalloproteinase-1 / blood
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / blood. Carcinoembryonic Antigen / blood. Female. Humans. Male. Middle Aged. Sensitivity and Specificity. Survival Rate


33. Chun YS, Vauthey JN, Ribero D, Donadon M, Mullen JT, Eng C, Madoff DC, Chang DZ, Ho L, Kopetz S, Wei SH, Curley SA, Abdalla EK: Systemic chemotherapy and two-stage hepatectomy for extensive bilateral colorectal liver metastases: perioperative safety and survival. J Gastrointest Surg; 2007 Nov;11(11):1498-504; discussion 1504-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic chemotherapy and two-stage hepatectomy for extensive bilateral colorectal liver metastases: perioperative safety and survival.
  • BACKGROUND: Two-stage hepatectomy has been proposed for patients with bilateral colorectal liver metastases (CLM).
  • [MeSH-major] Hepatectomy / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colorectal Neoplasms / pathology. Disease-Free Survival. Female. Humans. Length of Stay. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasms, Multiple Primary / surgery. Risk Assessment

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2004 Dec;240(6):1052-61; discussion 1061-4 [15570210.001]
  • [Cites] Ann Surg Oncol. 2006 Oct;13(10 ):1261-8 [16947009.001]
  • [Cites] Eur J Surg Oncol. 2007 Apr;33(3):329-35 [17140759.001]
  • [Cites] Ann Surg. 2000 Dec;232(6):777-85 [11088072.001]
  • [Cites] Ann Surg. 2005 May;241(5):715-22, discussion 722-4 [15849507.001]
  • [Cites] Hepatogastroenterology. 2005 May-Jun;52(63):913-9 [15966231.001]
  • [Cites] Semin Oncol. 2007 Apr;34(2 Suppl 1):S7-11 [17449352.001]
  • [Cites] Arch Surg. 2002 Jun;137(6):675-80; discussion 680-1 [12049538.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2065-72 [16648507.001]
  • [Cites] Ann Surg. 2004 Sep;240(3):438-47; discussion 447-50 [15319715.001]
  • [Cites] Ann Surg. 2000 May;231(5):743-51 [10767796.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):205-13 [15273542.001]
  • [Cites] J Gastrointest Surg. 2003 Dec;7(8):1082-8 [14675719.001]
  • [Cites] Ann Surg. 2004 Dec;240(6):1037-49; discussion 1049-51 [15570209.001]
  • [Cites] Ann Surg. 2004 Oct;240(4):644-57; discussion 657-8 [15383792.001]
  • [Cites] Ann Surg. 2004 May;239(5):722-30; discussion 730-2 [15082977.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):818-25; discussion 825-7 [15166961.001]
  • [Cites] J Am Coll Surg. 2003 Jul;197(1):164-70 [12831938.001]
  • (PMID = 17849166.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Liu YJ, Wang GM, Zhang YK, Zhang L, Sun LA, Lin ZM, Zhu TY: [The clinical characteristic of adrenal metastatic tumor]. Zhonghua Wai Ke Za Zhi; 2007 Jan 15;45(2):124-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Lung and hepatocellular carcinoma were the most common primary tumor of adrenal metastatic tumor, which about 36.9% (38/103) and 42.7% (44/103) of all cases, followed by renal carcinoma 6.8% (7/103), colorectal carcinoma 4.9% (5/103), stomach carcinoma 3.9% (4/103), breast cancer 1.9% (2/103), unknown primary tumor 2.9% (3/103).
  • The mean interval from detection of primary tumor to adrenal metastasis was 9.5 months.
  • CONCLUSIONS: There is no particular presentation of clinic and imaging, diagnosis depending on history, follow-up and the pathological presentation of primary tumor.
  • When the primary tumor could be resected or be well controlled, and there is no other evidence of metastasis, adrenalectomy is recommended.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Hepatocellular / pathology. Combined Modality Therapy. Female. Humans. Liver Neoplasms / pathology. Lung Neoplasms / pathology. Male. Middle Aged. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17418043.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


35. Nanashima A, Sumida Y, Abo T, Tobinaga S, Takeshita H, Hidaka S, Yasutake T, Nagayasu T, Mine M, Sawai T: A modified grading system for post-hepatectomy metastatic liver cancer originating from colorectal carcinoma. J Surg Oncol; 2008 Oct 1;98(5):363-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A modified grading system for post-hepatectomy metastatic liver cancer originating from colorectal carcinoma.
  • BACKGROUND AND OBJECTIVES: There is no appropriate grading system for prediction of survival of patients with metastatic liver cancer (MLC) from colorectal carcinoma.
  • METHODS: We compared predictive accuracies of survival of 121 Japanese MLC patients of five systems, including clinical risk score (CRS) proposed by Memorial-Sloan-Kettering-Cancer-Center, original H-number (OHN) by Japanese Society for Cancer of the Colon and Rectum, revised H-number (RHN) and Grade by the same society (GJSCCR), and our modified Grade (MGJSCCR) based on OHN and presence of primary lymph node metastasis.
  • [MeSH-major] Colorectal Neoplasms / pathology. Liver Neoplasms / pathology. Liver Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Hepatectomy. Humans. Japan. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Predictive Value of Tests. Survival Analysis. Survival Rate


36. Limaye PB, Alarcón G, Walls AL, Nalesnik MA, Michalopoulos GK, Demetris AJ, Ochoa ER: Expression of specific hepatocyte and cholangiocyte transcription factors in human liver disease and embryonic development. Lab Invest; 2008 Aug;88(8):865-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of specific hepatocyte and cholangiocyte transcription factors in human liver disease and embryonic development.
  • Studies in rodent liver have shown that alterations in transcription factor expression determine lineage specification during fetal liver development and signify transdifferentiation of cells of the biliary compartment into 'oval' cells and eventually hepatocytes in adult liver.
  • We examined the cellular localization of hepatocyte- or BEC-associated transcription factors in human fetal and adult liver and in diseases in which transdifferentiation between hepatocytes and biliary cells may play a role.
  • In the normal adult human liver, hepatocyte nuclear factor (HNF)4 alpha and HNF6 appeared exclusively in hepatocytes; HNF1beta, HNF3alpha, and HNF3beta were observed only in BEC.
  • We further examined expression of transcription factors in massive hepatic necrosis and in specific types of chronic liver disease.
  • Similarly, HNF3beta that is expressed only in BEC in normal adult liver was also observed in hepatocytes in primary biliary cirrhosis and chronic biliary obstruction.

  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hepatol. 1997 Feb;26(2):343-52 [9059956.001]
  • [Cites] Carcinogenesis. 1996 Oct;17(10):2143-51 [8895481.001]
  • [Cites] Mod Pathol. 1997 Apr;10(4):348-53 [9110297.001]
  • [Cites] Am J Pathol. 1997 Oct;151(4):905-9 [9327722.001]
  • [Cites] Am J Pathol. 1998 Mar;152(3):771-9 [9502419.001]
  • [Cites] Hepatology. 1998 Oct;28(4):980-5 [9755234.001]
  • [Cites] J Hepatol. 1998 Sep;29(3):455-63 [9764994.001]
  • [Cites] Genes Dev. 2000 Feb 15;14(4):464-74 [10691738.001]
  • [Cites] Mech Dev. 2000 Mar 15;92(1):83-8 [10704889.001]
  • [Cites] Dev Dyn. 2000 Oct;219(2):131-42 [11002334.001]
  • [Cites] Mol Cell Biol. 2001 Feb;21(4):1393-403 [11158324.001]
  • [Cites] Hepatology. 2001 Dec;34(6):1184-92 [11732008.001]
  • [Cites] Development. 2002 Apr;129(8):1819-28 [11934848.001]
  • [Cites] Development. 2002 Apr;129(8):1829-38 [11934849.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1695-703 [12000721.001]
  • [Cites] Mech Dev. 2003 Jan;120(1):81-7 [12490298.001]
  • [Cites] Semin Liver Dis. 2003 Nov;23(4):373-84 [14722814.001]
  • [Cites] Carcinogenesis. 1987 Nov;8(11):1737-40 [3664968.001]
  • [Cites] Cancer Res. 1989 Mar 15;49(6):1541-7 [2466557.001]
  • [Cites] Arch Pathol Lab Med. 1990 Apr;114(4):403-6 [2322100.001]
  • [Cites] J Cell Biol. 1994 Jul;126(1):223-33 [8027180.001]
  • [Cites] Histol Histopathol. 1995 Apr;10(2):433-56 [7599440.001]
  • [Cites] Hepatology. 1995 Oct;22(4 Pt 1):1243-53 [7557877.001]
  • [Cites] Pathol Res Pract. 1995 Jul;191(6):513-24 [7479372.001]
  • [Cites] Hepatology. 1996 Jan;23(1):62-70 [8550050.001]
  • [Cites] Hepatology. 2005 Mar;41(3):535-44 [15726663.001]
  • [Cites] Nature. 2005 Jun 16;435(7044):944-7 [15959514.001]
  • [Cites] Cell Cycle. 2006 Jan;5(2):168-71 [16357531.001]
  • [Cites] Hepatology. 2006 Feb;43(2 Suppl 1):S45-53 [16447274.001]
  • [Cites] Hepatology. 2007 Mar;45(3):716-24 [17326146.001]
  • [Cites] J Cell Physiol. 2007 Nov;213(2):286-300 [17559071.001]
  • [Cites] Cell. 1996 Feb 23;84(4):575-85 [8598044.001]
  • [Cites] Am J Pathol. 1996 Aug;149(2):439-48 [8701983.001]
  • [Cites] Science. 1997 Apr 4;276(5309):60-6 [9082986.001]
  • (PMID = 18574450.001).
  • [ISSN] 1530-0307
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] ENG
  • [Grant] United States / NCATS NIH HHS / TR / UL1 TR000005; United States / NCI NIH HHS / CA / CA35373; United States / NIDDK NIH HHS / DK / KO8 5K08DK65880; United States / NCI NIH HHS / CA / R01 CA103958; United States / NCI NIH HHS / CA / CA103958-05; United States / NCI NIH HHS / CA / R01 CA103958-05; United States / NCI NIH HHS / CA / R01 CA035373; United States / NCI NIH HHS / CA / CA30241; United States / NCI NIH HHS / CA / R01 CA035373-26; United States / NIDDK NIH HHS / DK / K08 DK065880; United States / NCI NIH HHS / CA / CA035373-26
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Transcription Factors
  • [Other-IDs] NLM/ NIHMS85375; NLM/ PMC2631390
  •  go-up   go-down


37. Viviani S, Carrieri P, Bah E, Hall AJ, Kirk GD, Mendy M, Montesano R, Plymoth A, Sam O, Van der Sande M, Whittle H, Hainaut P, Gambia Hepatitis Intervention Study: 20 years into the Gambia Hepatitis Intervention Study: assessment of initial hypotheses and prospects for evaluation of protective effectiveness against liver cancer. Cancer Epidemiol Biomarkers Prev; 2008 Nov;17(11):3216-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 20 years into the Gambia Hepatitis Intervention Study: assessment of initial hypotheses and prospects for evaluation of protective effectiveness against liver cancer.
  • Primary hepatocellular carcinoma is the commonest cancer in The Gambia.
  • The Gambia Hepatitis Intervention Study (GHIS) was established in 1986 to evaluate the protective effectiveness of infant hepatitis B immunization in the prevention of chronic liver disease, particularly, hepatocellular carcinoma and cirrhosis later in adult life.
  • [MeSH-major] Carcinoma, Hepatocellular / prevention & control. Carcinoma, Hepatocellular / virology. Hepatitis B / complications. Hepatitis B / prevention & control. Hepatitis B Vaccines / therapeutic use. Immunization Programs / organization & administration. Liver Neoplasms / prevention & control. Liver Neoplasms / virology

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18990765.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U190071425; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hepatitis B Vaccines
  • [Investigator] Hall AJ; Inskip HM; Loik F; Day NE; O'Conor G; Bosch X; Muir CS; Parkin M; Munoz N; Tomatis L; Greenwood B; Whittle H; Ryder R; Oldfield FS; Njie AB; Smith PG; Coursaget P
  •  go-up   go-down


38. Kim HO, Hwang SI, Hong HP, Yoo CH: Radiofrequency ablation for metachronous hepatic metastases from gastric cancer. Surg Laparosc Endosc Percutan Tech; 2009 Jun;19(3):208-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiofrequency ablation for metachronous hepatic metastases from gastric cancer.
  • Between January 2000 and February 2008, we retrospectively reviewed 7 cases for which RFA was performed for treating metachronous hepatic metastases after resection of the primary gastric adenocarcinoma.
  • Combination therapy such as systemic chemotherapy or hepatic arterial infusion chemotherapy adjuvant to RFA would more reasonable for treating hepatic metastases from gastric cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Catheter Ablation / methods. Hepatectomy / methods. Liver Neoplasms / surgery. Neoplasms, Second Primary / surgery. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biopsy, Needle. Female. Follow-Up Studies. Gastrectomy / methods. Humans. Male. Middle Aged. Retrospective Studies. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542847.001).
  • [ISSN] 1534-4908
  • [Journal-full-title] Surgical laparoscopy, endoscopy & percutaneous techniques
  • [ISO-abbreviation] Surg Laparosc Endosc Percutan Tech
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Zhang HZ, Dong SX, Zhou ZX, Shao YF: [Outcome of surgical therapy for liver metastasis of colorectal cancer: analysis of 75 cases]. Zhonghua Yi Xue Za Zhi; 2007 Jun 5;87(21):1457-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Outcome of surgical therapy for liver metastasis of colorectal cancer: analysis of 75 cases].
  • OBJECTIVE: To explore the strategy to improve the long term survival of liver metastasis of colorectal cancer after surgical treatment.
  • METHODS: The clinical data of 75 patients with liver metastasis of colorectal cancer, 43 males and 32 females, aged 51.4, who received hepatectomy between January 1981 and November 2005, were analyzed.
  • RESULTS: The primary tumor site was colon in 39 cases, and rectum in 36 cases.
  • Liver metastasis was synchronous in 59 patients, and metachronous in 16 patients.
  • 45 patients received simultaneous liver and colorectal resection, 29 patients received metachronous resection, and 1 patient did not receive primary rectal cancer resection.
  • CONCLUSION: Surgical resection of liver metastasis of colorectal cancer significantly prolongs the survival time, and resection of all liver deposits and the extrahepatic disease is the most important factor influencing survival.
  • [MeSH-major] Colorectal Neoplasms / pathology. Liver Neoplasms / secondary. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome


40. Giovinale M, Fonnesu C, Soriano A, Cerquaglia C, Curigliano V, Verrecchia E, De Socio G, Gasbarrini G, Manna R: Atypical sarcoidosis: case reports and review of the literature. Eur Rev Med Pharmacol Sci; 2009 Mar;13 Suppl 1:37-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Granulomatous inflammation of the spleen and the liver is common in patients with systemic sarcoidosis, while hepatosplenic enlargement is unusual and splenic involvement rare.
  • The second case is a 66-year-old woman with a recent weight loss (8 kg in two months) and alterated liver function tests (AST 61 U/l, ALT 72 U/l, Alkaline phosphatase 748 U/l, g-GT 381 U/l).
  • Since she had a familiar history of colon cancer, abdominal US scan, abdominal CT scan and MRI were performed and showed inter-aorto-caval lymphadenopathies and discreet multiple bilobar hepatic and splenic substitutive lesions, with no signs of primary tumor.
  • This latter required to differentiate liver and/or spleen sarcoidosis from tuberculosis and other infections, primary biliary cirrhosis, metastasis or malignant lymphoma.
  • [MeSH-major] Liver Diseases / complications. Sarcoidosis / complications. Splenic Diseases / complications
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Tomography, X-Ray Computed


41. Gorgun E, Remzi FH, Manilich E, Preen M, Shen B, Fazio VW: Surgical outcome in patients with primary sclerosing cholangitis undergoing ileal pouch-anal anastomosis: a case-control study. Surgery; 2005 Oct;138(4):631-7; discussion 637-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical outcome in patients with primary sclerosing cholangitis undergoing ileal pouch-anal anastomosis: a case-control study.
  • BACKGROUND: The outcome of restorative proctocolectomy in the setting of chronic ulcerative colitis complicated by primary sclerosing cholangitis (PSC) is not clear.
  • The purpose of this study was to determine the surgical outcome, risk of dysplasia/cancer, morbidity/mortality, long-term results, and functional and quality of life results in patients with inflammatory bowel disease (IBD) and PSC who underwent restorative proctocolectomy with ileal pouch-anal anastomosis and compare them in a case-matched study.
  • Postoperative morbidity, incidence of neoplasia/cancer in the resected specimen, pouchitis, pouch failure, long-term mortality, and 5-year survival rates were compared between the groups.
  • A higher incidence of cancer (14% vs 5%, P = .02) and dysplasia in the resected specimen (40% vs 7%, P < .001), an associated increased risk of postoperative pelvic sepsis (14% vs 5%, P = .02), and higher long-term mortality (35% vs 4%, P < .001) were found in the PSC group compared with control group with no associated PSC.
  • The majority, 13 of 23 (57%), of the deaths in the PSC group were a result of liver disease.
  • CONCLUSIONS: PSC-associated IBD patients after restorative proctocolectomy have a higher risk of neoplasia/cancer in the resected specimen, postoperative pelvic sepsis, and higher long-term mortality.
  • [MeSH-minor] Adult. Case-Control Studies. Female. Humans. Infection / etiology. Intestinal Neoplasms / etiology. Male. Middle Aged. Pelvis. Quality of Life. Risk Factors. Survival Analysis

  • Genetic Alliance. consumer health - Primary sclerosing cholangitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16269291.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Floer M, Binion DG, Nelson VM, Manley S, Wellner M, Sadeghi S, Behmaram B, Sewell C, Otterson MF, Kucharzik T, Rafiee P: Role of MutS homolog 2 (MSH2) in intestinal myofibroblast proliferation during Crohn's disease stricture formation. Am J Physiol Gastrointest Liver Physiol; 2008 Sep;295(3):G581-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Control and CD bowel tissues were used to generate primary cultures of muscularis mucosa myofibroblasts, which were assessed directly or following stimulation with TNF-alpha/LPS or H2O2.

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • Hazardous Substances Data Bank. SIMVASTATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 2008 Jan;128(1):203-13 [17611581.001]
  • [Cites] Gut. 2007 Jan;56(1):130-9 [17172588.001]
  • [Cites] Ann Rheum Dis. 2000 May;59(5):386-9 [10784522.001]
  • [Cites] Free Radic Biol Med. 2000 Nov 1;29(9):881-8 [11063913.001]
  • [Cites] Genes Dev. 2001 Mar 15;15(6):724-36 [11274057.001]
  • [Cites] Inflamm Bowel Dis. 2001 Aug;7(3):226-36 [11515849.001]
  • [Cites] Atherosclerosis. 2002 Mar;161(1):17-26 [11882313.001]
  • [Cites] Am J Physiol Cell Physiol. 2002 Jul;283(1):C148-54 [12055083.001]
  • [Cites] Am J Epidemiol. 2002 Nov 15;156(10):885-902 [12419761.001]
  • [Cites] BMC Gastroenterol. 2001;1:5 [11481030.001]
  • [Cites] J Immunol. 2003 Feb 15;170(4):2214-20 [12574395.001]
  • [Cites] J Biol Chem. 2003 Mar 7;278(10):8508-15 [12496258.001]
  • [Cites] Thromb Haemost. 2003 Mar;89(3):530-7 [12624638.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Apr;305(1):78-85 [12649355.001]
  • [Cites] Free Radic Biol Med. 2003 Dec 15;35(12):1679-87 [14680690.001]
  • [Cites] Int J Colorectal Dis. 2004 Jul;19(4):325-33 [15060836.001]
  • [Cites] Coron Artery Dis. 2004 Aug;15(5):251-8 [15238821.001]
  • [Cites] Gastroenterology. 1988 Feb;94(2):257-65 [3335305.001]
  • [Cites] Dis Colon Rectum. 1990 Apr;33(4):271-6 [2323275.001]
  • [Cites] Mod Pathol. 1991 Jan;4(1):87-90 [2020666.001]
  • [Cites] Cancer Res. 1991 Jun 15;51(12):3075-9 [2039987.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Aug 5;225(1):186-90 [8769115.001]
  • [Cites] J Biol Chem. 1998 Jul 31;273(31):19895-901 [9677427.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 15;95(19):11301-6 [9736731.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Ann Rheum Dis. 2004 Dec;63(12):1695-9 [15547100.001]
  • [Cites] Semin Vasc Med. 2004 Nov;4(4):347-56 [15861311.001]
  • [Cites] Am J Gastroenterol. 2005 Dec;100(12):2724-9 [16393226.001]
  • [Cites] J Virol. 2007 Feb;81(3):1492-501 [17108035.001]
  • [Cites] Am J Gastroenterol. 2007 Feb;102(2):439-48 [17156147.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2007 May;292(5):G1323-36 [17218473.001]
  • [Cites] Gastroenterology. 2007 Jul;133(1):137-49 [17631138.001]
  • [Cites] Heart. 2007 Aug;93(8):933-9 [17344325.001]
  • [Cites] J Gastrointest Surg. 2007 Dec;11(12):1692-8; dicussion 1698 [17940830.001]
  • [Cites] Respir Med. 2006 Feb;100(2):202-11 [16005622.001]
  • [Cites] World J Gastroenterol. 2006 Aug 14;12(30):4807-12 [16937461.001]
  • [Cites] J Mol Histol. 2006 Sep;37(5-7):301-7 [17080293.001]
  • [Cites] Dig Dis Sci. 2000 Feb;45(2):378-84 [10711455.001]
  • (PMID = 18635600.001).
  • [ISSN] 0193-1857
  • [Journal-full-title] American journal of physiology. Gastrointestinal and liver physiology
  • [ISO-abbreviation] Am. J. Physiol. Gastrointest. Liver Physiol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK065948
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / G-T mismatch-binding protein; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0 / Lipopolysaccharides; 0 / MSH3 protein, human; 0 / Proliferating Cell Nuclear Antigen; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Tumor Necrosis Factor-alpha; AGG2FN16EV / Simvastatin; BBX060AN9V / Hydrogen Peroxide; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein; VC2W18DGKR / Thymidine
  • [Other-IDs] NLM/ PMC2536780
  •  go-up   go-down


43. Gu YK, Fan WJ, Huang JH, Zhang L, Gao F: [Efficacy of CT-guided intra-tumoral dehydrated ethanol injection on lung metastasis from liver cancer]. Ai Zheng; 2007 Oct;26(10):1112-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of CT-guided intra-tumoral dehydrated ethanol injection on lung metastasis from liver cancer].
  • BACKGROUND & OBJECTIVE: Lung is the most common organ to which liver cancer cells transfer.
  • For the patients only with lung metastases whose primary liver cancers were in good control, treatment efficacy on lung metastasis is a crucial prognosis factor.
  • This study was to evaluate the efficacy of CT-guided intra-tumoral dehydrated ethanol injection on lung metastasis from liver cancer.
  • 2006, 17 patients with 37 lung metastatic lesions, whose primary liver cancers were in good control after operation or transcatheter artery chemoembolization (TACE), received CT-guided intra-tumoral dehydrated ethanol injection at Cancer Center of Sun Yat-sen University.
  • All primary liver cancers were in good control during follow-up.
  • CONCLUSION: CT-guided intra-tumoral dehydrated ethanol injection in treating lung metastasis from liver cancer is an effective, micro-invasive method with few complications.
  • [MeSH-major] Ethanol / therapeutic use. Liver Neoplasms / pathology. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Chemoembolization, Therapeutic / methods. Female. Humans. Injections, Intralesional. Iodized Oil. Male. Middle Aged. Survival Rate. Tomography, X-Ray Computed. Young Adult

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17927883.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 3K9958V90M / Ethanol; 8001-40-9 / Iodized Oil
  •  go-up   go-down


44. Ye Y, Xie X, Yu J, Zhou L, Xie H, Jiang G, Yu X, Zhang W, Wu J, Zheng S: Involvement of Th17 and Th1 effector responses in patients with Hepatitis B. J Clin Immunol; 2010 Jul;30(4):546-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Local production of cytokines within the liver may play a pivotal role in the regulation of pathophysiological processes during inflammation.
  • The purpose of this study was to quantify intrahepatic expression of Th1, Th2, Th17, and Treg-associated cytokines or transcription factors in patients with acute hepatitis B or chronic hepatitis B (CHB) and to analyze their relative roles in the promotion and regulation of hepatitis B virus (HBV)-associated liver diseases.
  • METHODS: Distribution and expression of IL-17, IFN-gamma, IL-4, Foxp3, and other cytokines in liver tissues were detected by immunohistochemistry and real-time quantitative PCR.
  • Patients with hepatitis B were compared with patients with chronic hepatitis C, primary biliary cirrhosis, alcoholic liver cirrhosis, and healthy controls.
  • RESULTS: The frequencies of intrahepatic IL-17 and IFN-gamma-producing cells in patients with HBV-associated liver dysfunction were much higher than that of IL-4 and Foxp3-positive cells.
  • There are more IL-17-producing cells than IFN-gamma-producing cells accumulating in the liver with severe hepatocellular damage.
  • Liver IL-17-producing cell infiltration was positively associated with the grade of liver inflammation in CHB and positively correlated to intrahepatic IL-8 expression (r=0.801, p<0.01) or neutrophil infiltration (r=0.917, p<0.01).
  • Inappropriate, excessive, and non-specific Th17 and Th1 effector responses may be involved in the pathogenesis of HBV-associated liver inflammation and hepatocellular damage.
  • Th17 response, especially, may exacerbate the inflammatory processes leading to liver failure.
  • IL-17-mediating liver neutrophil recruitment via induction of IL-8 may be one potential mechanism of liver injury in patients with hepatitis B.
  • An improved understanding of the factors that influence the differentiation and function of these cell types in vivo will be of great importance to the future development of immune therapies in HBV-associated liver disease.
  • [MeSH-minor] Adult. Aged. CD4-Positive T-Lymphocytes / immunology. Case-Control Studies. Cytokines / biosynthesis. Female. Humans. Liver / immunology. Liver / metabolism. Male. Middle Aged. T-Lymphocytes, Regulatory / immunology. Transcription Factors / biosynthesis

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2005 Aug;79(15):9369-80 [16014900.001]
  • [Cites] Annu Rev Immunol. 1995;13:251-76 [7612223.001]
  • [Cites] Int Rev Immunol. 1998;16(5-6):541-51 [9646176.001]
  • [Cites] Ann Surg Oncol. 2008 Dec;15(12):3494-502 [18830757.001]
  • [Cites] Hepatology. 2009 May;49(5 Suppl):S13-21 [19399811.001]
  • [Cites] Hepatology. 2010 Jan;51(1):81-91 [19842207.001]
  • [Cites] Hepatology. 2009 Feb;49(2):646-57 [19177575.001]
  • [Cites] Nature. 2006 May 11;441(7090):235-8 [16648838.001]
  • [Cites] Annu Rev Immunol. 1995;13:29-60 [7612225.001]
  • [Cites] Liver Int. 2006 Oct;26(8):912-9 [16953830.001]
  • [Cites] Annu Rev Immunol. 2009;27:485-517 [19132915.001]
  • [Cites] Hepatology. 1997 Apr;25(4):1022-7 [9096614.001]
  • [Cites] J Med Virol. 2003 Nov;71(3):376-84 [12966542.001]
  • [Cites] J Immunol. 1999 Jun 1;162(11):6503-9 [10352265.001]
  • [Cites] Int Arch Allergy Immunol. 2001 Nov;126(3):179-84 [11752873.001]
  • [Cites] Hepatology. 2009 May;49(5 Suppl):S45-55 [19399792.001]
  • [Cites] J Hepatol. 2007 Oct;47(4):598-607 [17692984.001]
  • [Cites] Nat Immunol. 2005 Nov;6(11):1123-32 [16200070.001]
  • [Cites] J Clin Invest. 1997 Jun 15;99(12):3025-33 [9185527.001]
  • [Cites] Annu Rev Immunol. 2009;27:147-63 [19302037.001]
  • [Cites] Nat Rev Immunol. 2005 Mar;5(3):215-29 [15738952.001]
  • [Cites] Clin Liver Dis. 2007 Nov;11(4):727-59, vii-viii [17981227.001]
  • [Cites] Hepatology. 1995 Jul;22(1):61-8 [7601434.001]
  • [Cites] Nat Immunol. 2005 Nov;6(11):1133-41 [16200068.001]
  • [Cites] Hepatol Res. 2007 Apr;37(4):248-54 [17397512.001]
  • [Cites] Antivir Ther. 1998;3(Suppl 3):13-24 [10726052.001]
  • [Cites] Cancer Res. 2009 Mar 1;69(5):2010-7 [19244111.001]
  • [Cites] Clin Microbiol Infect. 2005 Jan;11(1):52-6 [15649304.001]
  • [Cites] J Autoimmun. 2009 Feb;32(1):43-51 [19101114.001]
  • [Cites] J Hepatol. 2009 May;50(5):980-9 [19329213.001]
  • [Cites] Nat Med. 2007 Feb;13(2):139-45 [17290272.001]
  • [Cites] J Immunol. 1999 Feb 15;162(4):2347-52 [9973514.001]
  • [Cites] Immunol Rev. 2008 Jun;223:87-113 [18613831.001]
  • [Cites] Gastroenterology. 1999 Sep;117(3):645-52 [10464141.001]
  • (PMID = 20393789.001).
  • [ISSN] 1573-2592
  • [Journal-full-title] Journal of clinical immunology
  • [ISO-abbreviation] J. Clin. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-17; 0 / Transcription Factors
  •  go-up   go-down


45. Verslype C, Libbrecht L: The multidisciplinary management of gastrointestinal cancer. The diagnostic and therapeutic approach for primary solid liver tumours in adults. Best Pract Res Clin Gastroenterol; 2007;21(6):983-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The multidisciplinary management of gastrointestinal cancer. The diagnostic and therapeutic approach for primary solid liver tumours in adults.
  • The finding of a focal solid liver lesion represents a challenge for the clinician in terms of the most optimal diagnostic and therapeutic algorithm.
  • Tumours may arise from hepatocytes (hepatocellular adenoma, dysplastic nodules and carcinoma), bile ducts (cholangiocarcinoma) or mesenchymal tissue (hemangioma, epithelioid haemangioendothelioma), or are metastases from primary tumours outside the liver.
  • However, small hypervascular lesions in a cirrhotic liver may be difficult to characterise.
  • The therapy of a focal liver lesion is determined by its natural history and the functional status of the surrounding liver parenchyma.
  • Selected patients with primary liver cancer are candidates for liver transplantation, while patients with advanced malignant tumours have a poor outcome.
  • [MeSH-major] Bile Duct Neoplasms. Liver Cirrhosis / complications. Liver Neoplasms. Precancerous Conditions
  • [MeSH-minor] Adenoma, Liver Cell / diagnosis. Adenoma, Liver Cell / etiology. Adenoma, Liver Cell / therapy. Adult. Bile Ducts, Intrahepatic / pathology. Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / etiology. Carcinoma, Hepatocellular / therapy. Cholangiocarcinoma / diagnosis. Cholangiocarcinoma / etiology. Cholangiocarcinoma / therapy. Diagnosis, Differential. Focal Nodular Hyperplasia / diagnosis. Focal Nodular Hyperplasia / etiology. Focal Nodular Hyperplasia / therapy. Hemangioma / diagnosis. Hemangioma / etiology. Hemangioma / therapy. Humans

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18070699.001).
  • [ISSN] 1521-6918
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 47
  •  go-up   go-down


46. Kim KH, Kim SH, Kim SH, Back JH, Park MJ, Kim JM: Cyclooxygenase-2 and inducible nitric oxide synthase expression in thyroid neoplasms and their clinicopathological correlation. J Korean Med Sci; 2006 Dec;21(6):1064-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In PTC, COX-2 and iNOS were significantly overexpressed in patients over 45 yr of age (p=0.029, p=0.041), and iNOS expression was increased in patients with a large primary tumor (p=0.028).
  • [MeSH-minor] Adult. Aged. Female. Gene Expression Profiling. Humans. Male. Middle Aged. Reproducibility of Results. Sensitivity and Specificity. Statistics as Topic. Tissue Distribution

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FASEB J. 1998 Sep;12(12):1063-73 [9737710.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1998;38:97-120 [9597150.001]
  • [Cites] Thyroid. 1999 Feb;9(2):113-7 [10090309.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2001 Sep;281(3):G688-96 [11518681.001]
  • [Cites] J Clin Gastroenterol. 2001 Nov-Dec;33(5):383-8 [11606854.001]
  • [Cites] Ann Clin Lab Sci. 2001 Oct;31(4):325-48 [11688844.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jan;87(1):358-63 [11788675.001]
  • [Cites] J Pathol. 2002 Feb;196(2):171-9 [11793368.001]
  • [Cites] Laryngoscope. 2002 Feb;112(2):238-42 [11889377.001]
  • [Cites] Am J Clin Pathol. 2002 Apr;117(4):546-51 [11939728.001]
  • [Cites] Prostate. 2002 Nov 1;53(3):232-40 [12386924.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):961-8 [12631593.001]
  • [Cites] Endocr Pathol. 2002 Winter;13(4):331-40 [12665651.001]
  • [Cites] Histopathology. 2003 May;42(5):492-7 [12713627.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1604-10 [12738712.001]
  • [Cites] Pathol Int. 2003 Jul;53(7):434-9 [12828608.001]
  • [Cites] Korean J Intern Med. 2003 Dec;18(4):225-9 [14717230.001]
  • [Cites] Histopathology. 2004 May;44(5):490-7 [15139997.001]
  • [Cites] Br J Pharmacol. 1993 Mar;108(3):833-7 [7682140.001]
  • [Cites] Cancer Res. 1994 Mar 1;54(5):1352-4 [7509718.001]
  • [Cites] Cell. 1994 Sep 23;78(6):915-8 [7522969.001]
  • [Cites] Gastroenterology. 1994 Oct;107(4):1183-8 [7926468.001]
  • [Cites] Cancer Res. 1995 Feb 15;55(4):727-30 [7531613.001]
  • [Cites] Cell. 1996 Nov 29;87(5):803-9 [8945508.001]
  • [Cites] J Clin Invest. 1997 Jun 1;99(11):2625-34 [9169492.001]
  • [Cites] Mod Pathol. 1997 Jul;10(7):645-9 [9237172.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4926-31 [10987308.001]
  • [Cites] BJU Int. 2000 Oct;86(6):736-41 [11069387.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):303-8 [11196178.001]
  • [Cites] Antioxid Redox Signal. 2001 Apr;3(2):231-48 [11396478.001]
  • [Cites] Int J Urol. 2001 Jul;8(7):S35-9 [11442675.001]
  • [Cites] J Immunol. 1997 Sep 1;159(5):2445-51 [9278337.001]
  • [Cites] J Biol Chem. 1997 Dec 5;272(49):31138-48 [9388267.001]
  • [Cites] Cancer Metastasis Rev. 1998 Mar;17(1):107-18 [9544426.001]
  • [Cites] Laryngoscope. 1999 Jan;109(1):148-52 [9917057.001]
  • (PMID = 17179688.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; EC 1.14.13.39 / Nitric Oxide Synthase Type II; EC 1.14.99.1 / Cyclooxygenase 2
  • [Other-IDs] NLM/ PMC2721930
  •  go-up   go-down


47. Tarnowski M, Sieron AL: Adult stem cells and their ability to differentiate. Med Sci Monit; 2006 Aug;12(8):RA154-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult stem cells and their ability to differentiate.
  • This is a review of the current status of knowledge on adult stem cells as well as the criteria and evidence for their potential to transform into different cell types and cell lineages.
  • Reports on stem cell sources, focusing on tissues from adult subjects, were also investigated.
  • The question is still open about the characteristics of the primary stem cell.
  • Recent reports on cases of cancer in patients subjected to stem cell therapy are yet another controversial issue looked into in this review, although the pros and cons emerging from the results of published studies still do not provide satisfying evidence to fully understand this issue.
  • [MeSH-minor] Animals. Cell- and Tissue-Based Therapy. Humans. Liver Regeneration / physiology. Muscle, Skeletal / cytology. Nerve Tissue / cytology

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16865077.001).
  • [ISSN] 1234-1010
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 122
  •  go-up   go-down


48. Liu NN, Shen DL, Chen XQ, He YL: [Clinical analysis of 355 patients with bone metastasis of malignant tumors]. Zhonghua Zhong Liu Za Zhi; 2010 Mar;32(3):203-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common primary tumors were lung cancer in men and breast cancer in women.
  • Among them, it was 34.9 months in prostate cancer and 4.6 months in hepatocellular carcinoma.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / secondary. Combined Modality Therapy. Female. Humans. Liver Neoplasms / pathology. Male. Middle Aged. Pain / etiology. Pain Management. Prostatic Neoplasms / pathology. Quality of Life. Retrospective Studies. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20450589.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


49. Sun YL, Yin SY, Xie HY, Zhou L, Xue F, Wu LM, Gao F, Zheng SS: Stem-like cells in hepatitis B virus-associated cirrhotic livers and adjacent tissue to hepatocellular carcinomas possess the capacity of tumorigenicity. J Gastroenterol Hepatol; 2008 Aug;23(8 Pt 1):1280-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND AIM: Recent investigations demonstrate that adult stem cells may be targets for malignant transformation and that the stem-like cells in diseased livers possess the capacity of tumorigenicity in animal models.
  • METHODS: Twenty surgically resected HCCs and corresponding adjacent tissues as well as 10 cirrhotic liver tissues were collected and immunohistochemical staining were performed to detect the expression of CD34, Thy-1, CD133, and c-kit.
  • Then the non-cancerous tissues were transplanted into immunodeficient mice and the characteristics of the cells from primary tissue cultures were explored in vitro.
  • CONCLUSION: Our results suggest that the stem-like cells in cirrhotic livers possess the capacity of tumorigenicity and may contain candidates for HCC cancer stem cells.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Hepatitis B, Chronic / complications. Liver Cirrhosis / metabolism. Liver Neoplasms / metabolism. Neoplastic Stem Cells / metabolism
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18466286.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


50. Maluccio MA, Covey AM, Schubert J, Brody LA, Sofocleous CT, Getrajdman GI, DeMatteo R, Brown KT: Treatment of metastatic sarcoma to the liver with bland embolization. Cancer; 2006 Oct 1;107(7):1617-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of metastatic sarcoma to the liver with bland embolization.
  • BACKGROUND: The authors evaluated the impact of bland particle embolization on survival in patients with metastatic sarcoma to the liver.
  • METHODS: Twenty-four patients with liver-dominant metastases from sarcoma were treated with particle embolization from 1996 to 2002.
  • Primary tumors included 16 gastrointestinal stromal tumors (GISTs), 7 intestinal leiomyosarcomas, and 1 liposarcoma.
  • RESULTS: Nineteen patients had metachronous liver metastases, and the median disease-free interval was 22 months (range 10-156 months) from resection of the primary tumor.
  • Ten patients underwent prior liver resection for metastatic disease.
  • CONCLUSIONS: Bland embolization was efficacious in some patients with metastatic sarcoma to the liver.
  • [MeSH-major] Chemoembolization, Therapeutic. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Sarcoma / pathology. Sarcoma / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / administration & dosage. Benzamides. Female. Humans. Imatinib Mesylate. Magnetic Resonance Imaging. Male. Middle Aged. Piperazines / administration & dosage. Polyvinyl Alcohol / administration & dosage. Pyrimidines / administration & dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. POLYVINYL ALCOHOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 16955508.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; 9002-89-5 / Polyvinyl Alcohol
  •  go-up   go-down


51. Ahmadzadehfar H, Sabet A, Biermann K, Muckle M, Brockmann H, Kuhl C, Wilhelm K, Biersack HJ, Ezziddin S: The significance of 99mTc-MAA SPECT/CT liver perfusion imaging in treatment planning for 90Y-microsphere selective internal radiation treatment. J Nucl Med; 2010 Aug;51(8):1206-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The significance of 99mTc-MAA SPECT/CT liver perfusion imaging in treatment planning for 90Y-microsphere selective internal radiation treatment.
  • Selective internal radiation therapy (SIRT), a catheter-based liver-directed modality for treating primary and metastatic liver cancer, requires appropriate planning to maximize its therapeutic response and minimize its side effects. (99m)Tc-macroaggregated albumin (MAA) scanning should precede the therapy to detect any extrahepatic shunting to the lung or gastrointestinal tract.
  • METHODS: Ninety diagnostic hepatic angiograms with (99m)Tc-MAA were obtained for 76 patients with different types of cancer.
  • [MeSH-major] Liver / radionuclide imaging. Liver Circulation / physiology. Liver Neoplasms / drug therapy. Liver Neoplasms / radionuclide imaging. Radiopharmaceuticals. Technetium Tc 99m Aggregated Albumin. Yttrium Radioisotopes / therapeutic use
  • [MeSH-minor] Abdomen / radionuclide imaging. Adult. Aged. Aged, 80 and over. Data Interpretation, Statistical. Embolization, Therapeutic. Female. Gallbladder / metabolism. Gallbladder / radionuclide imaging. Humans. Image Interpretation, Computer-Assisted. Male. Microspheres. Middle Aged. Patient Care Planning. Radionuclide Angiography. Reference Standards. Tomography, Emission-Computed. Tomography, Emission-Computed, Single-Photon

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20660379.001).
  • [ISSN] 1535-5667
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0 / Technetium Tc 99m Aggregated Albumin; 0 / Yttrium Radioisotopes
  •  go-up   go-down


52. Chen PH, Lin YC, Tu HP, Chiang SL, Ko AM, Hsu CL, Chang YF, Ko YC: Important prognostic factors for the long-term survival of subjects with primary liver cancer in Taiwan: a hyperendemic area. Eur J Cancer; 2007 Apr;43(6):1076-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Important prognostic factors for the long-term survival of subjects with primary liver cancer in Taiwan: a hyperendemic area.
  • This study used a large-scale cancer database in determining the survival prognostic factors among primary liver cancer (PLC) subjects.
  • Particularly, subjects with adenocarcinoma and CC were more likely to die in other metastatic cancer.
  • [MeSH-major] Endemic Diseases / statistics & numerical data. Liver Neoplasms / mortality
  • [MeSH-minor] Adenocarcinoma / mortality. Adult. Age Distribution. Aged. Carcinoma, Hepatocellular / mortality. Cause of Death. Cholangiocarcinoma / mortality. Female. Humans. Male. Middle Aged. Prognosis. Sex Distribution. Survival Analysis. Taiwan / epidemiology

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17329095.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


53. Iancu C, Mocan LC, Todea-Iancu D, Mocan T, Acalovschi I, Ionescu D, Zaharie FV, Osian G, Puia CI, Muntean V: Host-related predictive factors for anastomotic leakage following large bowel resections for colorectal cancer. J Gastrointestin Liver Dis; 2008 Sep;17(3):299-303
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Host-related predictive factors for anastomotic leakage following large bowel resections for colorectal cancer.
  • AIM: To identify the risk, the host-related prognostic factors and their predictive value for anastomotic leakage after colorectal resections following cancer.
  • METHOD: 993 patients who underwent large bowel resection and primary anastomosis above 12 centimeters from the anal verge, without a temporary or permanent stoma at the Surgical Hospital No.3 (Cluj-Napoca, Romania) were retrospectively reviewed.
  • CONCLUSION. A serum protein level lower than 5.5 g/dl and serum hemoglobin lower than 9.4 g/dl could be considered as host-related predictive markers for anastomotic leak in large bowel resections for cancer.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anemia / complications. Blood Proteins / analysis. Female. Hemoglobins / analysis. Humans. Hypoproteinemia / complications. Logistic Models. Male. Middle Aged. Postoperative Complications. Prognosis. Retrospective Studies. Risk Factors

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18836623.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Blood Proteins; 0 / Hemoglobins
  •  go-up   go-down


54. Ishizone S, Maruta F, Saito H, Koide N, Sugiyama A, Nakayama J, Miyagawa S: Efficacy of S-1 for patients with peritoneal metastasis of gastric cancer. Chemotherapy; 2006;52(6):301-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of S-1 for patients with peritoneal metastasis of gastric cancer.
  • BACKGROUND: This study was designed to examine the efficacy and compliance of S-1 for the patients with peritoneal metastasis of gastric cancer.
  • METHODS: Sixteen consecutive patients with peritoneal metastasis of gastric cancer were treated with S-1.
  • We elucidated some factors to prolong the survival of the patients treated with S-1 for peritoneal metastasis: peritoneal metastasis without other distant metastases, the combination of S-1 treatment and gastrectomy, and low expression of thymidine phosphorylase mRNA in primary tumors.
  • CONCLUSIONS: S-1 showed a surprisingly long-term survival with minimum toxicity in patients with peritoneal metastasis of gastric cancer.
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Dihydrouracil Dehydrogenase (NADP) / metabolism. Drug Combinations. Female. Gastrectomy. Humans. Intestinal Neoplasms / pathology. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Orotate Phosphoribosyltransferase / metabolism. Patient Compliance. Survival Rate. Thymidine Phosphorylase / metabolism. Thymidylate Synthase / metabolism. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17008790.001).
  • [ISSN] 0009-3157
  • [Journal-full-title] Chemotherapy
  • [ISO-abbreviation] Chemotherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Biomarkers, Tumor; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; EC 1.3.1.2 / Dihydrouracil Dehydrogenase (NADP); EC 2.1.1.45 / Thymidylate Synthase; EC 2.4.2.10 / Orotate Phosphoribosyltransferase; EC 2.4.2.4 / Thymidine Phosphorylase
  •  go-up   go-down


55. Medine CN, Greenhough S, Hay DC: Role of stem-cell-derived hepatic endoderm in human drug discovery. Biochem Soc Trans; 2010 Aug;38(4):1033-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, the safety evaluation process is hindered by the availability and quality of primary human liver models with which to study drug toxicity.
  • In an attempt to overcome this limitation, research has focused on deriving human hepatocytes from a number of sources, including progenitors from fetal and adult liver, human cell lines derived from liver tumours, immortalized human hepatocytes and pluripotent stem cells.
  • The major hurdles in developing scalable and high-fidelity human hepatocytes from hepatic cell lines and fetal and adult progenitors have been limited organ availability, homogeneous cell purification, short-term cell culture, and the rapid loss of hepatocyte phenotype and function in culture.
  • Moreover, stem-cell-derived hepatic endoderm displays many of the functional attributes of primary human hepatocytes.
  • Our research is now focused on developing defined culture systems and improving cell culture microenvironments in order to improve our understanding of the mechanisms regulating human liver development.
  • [MeSH-major] Drug Discovery / methods. Embryonic Stem Cells / physiology. Endoderm / physiology. Liver / embryology
  • [MeSH-minor] Adult. Cell Culture Techniques / standards. Humans. Induced Pluripotent Stem Cells / cytology. Induced Pluripotent Stem Cells / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20658999.001).
  • [ISSN] 1470-8752
  • [Journal-full-title] Biochemical Society transactions
  • [ISO-abbreviation] Biochem. Soc. Trans.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  •  go-up   go-down


56. Fiaschetti V, Fiori R, Gaspari E, Crusco S, Simonetti G: Mixed hepatoblastoma in a young male adult: a case report and literature review. Case Rep Med; 2010;2010:919457
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed hepatoblastoma in a young male adult: a case report and literature review.
  • Hepatoblastoma (HB) is a rare malignant tumour of the liver and usually occurs in the first three years of life.
  • Most of these tumours arise in the embryo; hence it seems to be unusual that hepatoblastoma occurs in adults and is an exceptional cause of primary malignant liver tumour in adult patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21113306.001).
  • [ISSN] 1687-9635
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2990241
  •  go-up   go-down


57. Zhang M, Li B, Yan LN, Yin F, Wen TF, Zeng Y, Zhao JC, Ma YK: Development of a survival evaluation model for liver transplant recipients with hepatocellular carcinoma secondary to hepatitis B. World J Gastroenterol; 2008 Feb 28;14(8):1280-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of a survival evaluation model for liver transplant recipients with hepatocellular carcinoma secondary to hepatitis B.
  • METHODS: We retrospectively examined a cohort of 150 consecutive primary cadaveric liver transplants with HCC in our center over 6 years.
  • The predictive power of a new model and the model for end stage liver disease was compared by the receiver operating characteristic curve.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Carcinoma, Hepatocellular / therapy. Hepatitis B / complications. Hepatitis B / therapy. Liver Neoplasms / etiology. Liver Neoplasms / therapy. Liver Transplantation / methods
  • [MeSH-minor] Adult. Aged. Cell Survival. Cohort Studies. Female. Humans. Liver Diseases / diagnosis. Liver Diseases / therapy. Male. Middle Aged. Proportional Hazards Models. Retrospective Studies


58. Leelawat K, Suksumek N, Leelawat S, Lek-Uthai U: Detection of VacA gene specific for Helicobactor pylori in hepatocellular carcinoma and cholangiocarcinoma specimens of Thai patients. Southeast Asian J Trop Med Public Health; 2007 Sep;38(5):881-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In order to investigate and compare the presence of Helicobacter pylori VacA in primary liver cancer specimens (12 hepatocellular carcinoma and 6 cholangiocarcinoma) and control liver specimens (7 non-primary liver cancer) from Thai patients who underwent liver resection, H. pylori VacA gene was assayed in extracted DNA by real-time polymerase chain reaction.
  • The selected amplicons revealed high homology compared with H. pylori VacA sequence. H. pylori VacA gene was detected in all primary liver cancer specimens and in 71% (5/7) of control liver specimens.
  • [MeSH-major] Bacterial Proteins / genetics. Carcinoma, Hepatocellular / microbiology. Cholangiocarcinoma / microbiology. Helicobacter Infections / microbiology. Helicobacter pylori / genetics. Liver Neoplasms / microbiology
  • [MeSH-minor] Adult. Aged. Base Sequence. Female. Humans. Male. Middle Aged. Molecular Sequence Data. Polymerase Chain Reaction / methods. Thailand

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18041306.001).
  • [ISSN] 0125-1562
  • [Journal-full-title] The Southeast Asian journal of tropical medicine and public health
  • [ISO-abbreviation] Southeast Asian J. Trop. Med. Public Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / VacA protein, Helicobacter pylori
  •  go-up   go-down


59. Heimbach JK, Gores GJ, Haddock MG, Alberts SR, Pedersen R, Kremers W, Nyberg SL, Ishitani MB, Rosen CB: Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma. Transplantation; 2006 Dec 27;82(12):1703-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma.
  • BACKGROUND: Sixty-five patients with unresectable hilar cholangiocarcinoma (CCA) have undergone orthotopic liver transplantation (OLT) after neoadjuvant chemoradiotherapy per a clinical care protocol developed in 1993.
  • Predictors of recurrence were older age, pretransplant cancer antigen (CA) 19-9 >100 U/ml, prior cholecystectomy, mass on cross-sectional imaging, residual tumor in explant >2 cm, tumor grade and perineural invasion in explant.
  • Underlying primary sclerosing cholangitis, percutaneous biliary intubation, gender, and other time points for CA 19-9 were not associated with recurrence.
  • Prolonged staging-to-OLT intervals for patients transplanted after implementation of model for end-stage liver disease (MELD) showed a trend toward increased recurrence.
  • [MeSH-major] Bile Duct Neoplasms / therapy. Bile Ducts, Intrahepatic. CA-19-9 Antigen / blood. Cholangiocarcinoma / therapy. Liver Transplantation. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adult. Age Factors. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Prognosis. Risk Factors


60. Mori M, Naruto T, Imagawa T, Murata T, Takei S, Tomiita M, Itoh Y, Fujikawa S, Yokota S: Methotrexate for the treatment of juvenile idiopathic arthritis: process to approval for JIA indication in Japan. Mod Rheumatol; 2009;19(1):1-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Methotrexate (MTX), the primary treatment for the articular-type juvenile idiopathic arthritis (JIA), is effective and brings about radiological improvement.
  • Patient compliance is good, and it is recognized that its known side effects, namely, disruption of liver function and induction of pulmonary lesions, are unlikely to be severe at the low MTX doses that are administered.
  • In Japan, MTX was granted approval in 1999 by the then Ministry of Health and Welfare specifically for treating rheumatoid arthritis in adult patients, allowing it be generally used in medical institutions for patients having National Health Insurance.

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Arthritis, Juvenile.
  • MedlinePlus Health Information. consumer health - Juvenile Arthritis.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2000 Mar 16;342(11):763-9 [10717011.001]
  • [Cites] Nihon Naika Gakkai Zasshi. 2007 Oct 10;96(10):2226-34 [18044160.001]
  • [Cites] J Rheumatol. 2000 Aug;27(8):1830-3 [10955319.001]
  • [Cites] Ann Rheum Dis. 2000 Nov;59 Suppl 1:i21-7 [11053081.001]
  • [Cites] Cochrane Database Syst Rev. 2001;(3):CD003129 [11687037.001]
  • [Cites] Ryumachi. 2002 Feb;42(1):76-9 [11925910.001]
  • [Cites] Arch Dis Child. 2003 Mar;88(3):197-200 [12598376.001]
  • [Cites] Arthritis Rheum. 2004 Jul;50(7):2191-201 [15248217.001]
  • [Cites] Ann Rheum Dis. 2004 Sep;63(9):1128-30 [15308522.001]
  • [Cites] Lancet. 1980 Nov 1;2(8201):944-6 [6107590.001]
  • [Cites] J Rheumatol. 1982 Jan-Feb;9(1):109-13 [7045358.001]
  • [Cites] Cancer Res. 1983 May;43(5):2342-5 [6572562.001]
  • [Cites] Arthritis Rheum. 1989 Jun;32(6):677-81 [2735961.001]
  • [Cites] J Rheumatol. 1990 Nov;17(11):1469-73 [2273487.001]
  • [Cites] N Engl J Med. 1992 Apr 16;326(16):1043-9 [1549149.001]
  • [Cites] Br J Rheumatol. 1993 Jan;32(1):73-7 [8422565.001]
  • [Cites] Semin Arthritis Rheum. 1993 Aug;23(1):34-46 [8235664.001]
  • [Cites] J Rheumatol. 1993 Sep;20(9):1573-7 [8164218.001]
  • [Cites] Eur J Clin Pharmacol. 1995;47(6):507-11 [7768253.001]
  • [Cites] J Rheumatol. 1995 Aug;22(8):1570-3 [7473485.001]
  • [Cites] Acta Paediatr Jpn. 1997 Apr;39(2):242-4 [9141265.001]
  • [Cites] Arthritis Rheum. 1997 Jul;40(7):1202-9 [9214419.001]
  • [Cites] Therapie. 1997 Mar-Apr;52(2):129-32 [9231507.001]
  • [Cites] J Rheumatol. 1997 Nov;24(11):2230-2 [9375889.001]
  • [Cites] Ann Rheum Dis. 1998 Jan;57(1):38-41 [9536821.001]
  • [Cites] J Pediatr. 1998 Aug;133(2):179-80 [9709702.001]
  • [Cites] Arthritis Rheum. 1998 Sep;41(9):1552-63 [9751087.001]
  • [Cites] N Engl J Med. 2005 Apr 21;352(16):1655-66 [15843668.001]
  • [Cites] Arthritis Rheum. 2000 Aug;43(8):1849-57 [10943876.001]
  • (PMID = 18815725.001).
  • [ISSN] 1439-7595
  • [Journal-full-title] Modern rheumatology
  • [ISO-abbreviation] Mod Rheumatol
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antirheumatic Agents; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 39
  • [Other-IDs] NLM/ PMC2638602
  •  go-up   go-down


61. Oshima T, Kawasaki T, Ohashi R, Hasegawa G, Jiang S, Umezu H, Aoyagi Y, Iwanari H, Tanaka T, Hamakubo T, Kodama T, Naito M: Downregulated P1 promoter-driven hepatocyte nuclear factor-4alpha expression in human colorectal carcinoma is a new prognostic factor against liver metastasis. Pathol Int; 2007 Feb;57(2):82-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Downregulated P1 promoter-driven hepatocyte nuclear factor-4alpha expression in human colorectal carcinoma is a new prognostic factor against liver metastasis.
  • Liver metastases are the most critical prognostic factors for patients with colorectal carcinomas (CRC).
  • It has been reported that the dysregulation of hepatocyte nuclear factor-4alpha (HNF4alpha) expression is linked to the development of CRC, gastric cancer and hepatocellular carcinoma.
  • Immunohistochemically, P1, P2, MUC1 and CD10 expression were evaluated in 63 cases of primary CRC.
  • There was a relationship between the loss of P1 expression and metachronous liver metastases, and the survival rate of the P1-negative patients without liver metastasis at the time of the primary CRC resection tended to be worse than that of the P1-positive patients.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma, Mucinous / metabolism. Colorectal Neoplasms / metabolism. Down-Regulation / physiology. Hepatocyte Nuclear Factor 4 / metabolism. Liver Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Disease Progression. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Mucin-1 / genetics. Mucin-1 / metabolism. Neprilysin / genetics. Neprilysin / metabolism. Prognosis. Promoter Regions, Genetic / genetics. Promoter Regions, Genetic / physiology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17300672.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HNF4A protein, human; 0 / Hepatocyte Nuclear Factor 4; 0 / Mucin-1; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


62. House MG, Ito H, Gönen M, Fong Y, Allen PJ, DeMatteo RP, Brennan MF, Blumgart LH, Jarnagin WR, D'Angelica MI: Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg; 2010 May;210(5):744-52, 752-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution.
  • BACKGROUND: This study analyzes factors associated with differences in long-term outcomes after hepatic resection for metastatic colorectal cancer over time.
  • STUDY DESIGN: Sixteen-hundred consecutive patients undergoing hepatic resection for metastatic colorectal cancer between 1985 and 2004 were analyzed retrospectively.
  • There were no differences in age, Clinical Risk Score, or number of hepatic metastases between the 2 groups; however, more recently treated patients (era II) had more lymph node-positive primary tumors, shorter disease-free intervals, more extrahepatic disease, and smaller tumors.
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / mortality. Hepatectomy. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Rectal Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Disease-Free Survival. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome. Young Adult


63. Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, Donehower RC, Fitch T, Picus J, Erlichman C: Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol; 2005 Sep 20;23(27):6657-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.
  • PURPOSE: Epidermal growth factor receptor/human epidermal growth factor receptor 1 (EGFR/HER1) and ligand expression is frequently seen in hepatocellular cancers (HCCs).
  • METHODS: The primary objective of this study was to determine the proportion of patients with advanced HCC who were progression-free at 6 months.
  • [MeSH-major] Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / pathology. Liver Neoplasms / drug therapy. Liver Neoplasms / pathology. Neoplasm Invasiveness / pathology. Quinazolines / administration & dosage
  • [MeSH-minor] Administration, Oral. Adult. Aged. Aged, 80 and over. Confidence Intervals. Dose-Response Relationship, Drug. Drug Administration Schedule. Erlotinib Hydrochloride. Female. Follow-Up Studies. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Probability. Protein Kinase Inhibitors / administration & dosage. Protein Kinase Inhibitors / adverse effects. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16170173.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CM / N0-1 CM17104
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride
  •  go-up   go-down


64. Chou LS, Lewis RE, Ippoliti C, Champlin RE, Kontoyiannis DP: Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients. Pharmacotherapy; 2007 Dec;27(12):1644-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients.
  • STUDY OBJECTIVES: To assess the effectiveness and tolerability of caspofungin as primary prophylaxis against invasive fungal infections in stem cell transplant recipients who are poor candidates for triazole or lipid amphotericin B prophylaxis due to renal or hepatic dysfunction, and to determine whether any patient characteristics are independently associated with an increased risk of breakthrough invasive fungal infection during caspofungin prophylaxis.
  • SETTING: Tertiary care comprehensive cancer center.
  • PATIENTS: One hundred twenty-three adult stem cell transplant recipients who received caspofungin 35-50 mg/day for up to 100 days after transplantation as primary antifungal prophylaxis between January 1, 2002, and June 30, 2005.
  • CONCLUSION: Caspofungin seems to be an effective and well-tolerated option for primary antifungal prophylaxis in the highly immunosuppressed stem cell transplant patient population.
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / adverse effects. Cancer Care Facilities. Female. Graft vs Host Disease / etiology. Humans. Infliximab. Liver Failure / complications. Male. Middle Aged. Multivariate Analysis. Opportunistic Infections / microbiology. Opportunistic Infections / prevention & control. Pseudomonas Infections / complications. Renal Insufficiency / complications. Retrospective Studies. Time Factors

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CASPOFUNGIN .
  • Hazardous Substances Data Bank. Infliximab .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18041885.001).
  • [ISSN] 0277-0008
  • [Journal-full-title] Pharmacotherapy
  • [ISO-abbreviation] Pharmacotherapy
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antifungal Agents; 0 / Echinocandins; 0 / Immunosuppressive Agents; B72HH48FLU / Infliximab; F0XDI6ZL63 / caspofungin
  •  go-up   go-down


65. Ebert MP, Model F, Mooney S, Hale K, Lograsso J, Tonnes-Priddy L, Hoffmann J, Csepregi A, Röcken C, Molnar B, Schulz HU, Malfertheiner P, Lofton-Day C: Aristaless-like homeobox-4 gene methylation is a potential marker for colorectal adenocarcinomas. Gastroenterology; 2006 Nov;131(5):1418-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & AIMS: The identification of novel genetic and epigenetic markers indicative of changes in the pathogenesis of colon cancer, along with easier-to-use, more sensitive assay methods, may improve the detection, treatment, and overall prognosis of this malignancy.
  • METHODS: Using methylation-specific arbitrarily primed polymerase chain reaction, a fragment of the Aristaless-like homeobox-4 (ALX4) gene that was highly methylated in colon adenomas and cancer was identified.
  • Methylation of ALX4 was analyzed in colorectal adenomas and cancers, in the liver metastases of patients with colorectal cancer, and in 61 other neoplasias, including gastric, esophageal, and hepatocellular cancer and cholangiocarcinoma.
  • ALX4 methylation was also analyzed in the serum of 30 patients with colon cancer.
  • RESULTS: ALX4 gene methylation was confirmed in colon adenomas (11/13) and more frequently present in primary colorectal cancers (30/47) compared with the normal colon mucosa (0/21) (P < .0001).
  • In addition, ALX4 methylation was frequently observed in adenocarcinomas of the esophagus (12/14), stomach (11/15), and bile ducts (4/5) compared with all other cancers (P < .001).
  • ALX4 gene methylation was also more frequently found in sera of patients with colon cancer compared with noncancer controls (P < .0001).
  • CONCLUSIONS: Apart from colon adenomas and primary and metastatic colorectal cancers, ALX4 is frequently methylated in adenocarcinomas of the gastrointestinal tract.
  • ALX4 gene methylation in sera of patients with cancer may thus serve as a methylation-specific test for colon and other gastrointestinal cancers.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Base Sequence. Colonic Polyps / genetics. DNA Methylation. Female. Humans. Male. Middle Aged. Molecular Sequence Data. Neoplasm Metastasis. Precancerous Conditions / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17101318.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ALX4 protein, human; 0 / DNA-Binding Proteins; 0 / Transcription Factors
  •  go-up   go-down


71. Thomas MB, Morris JS, Chadha R, Iwasaki M, Kaur H, Lin E, Kaseb A, Glover K, Davila M, Abbruzzese J: Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol; 2009 Feb 20;27(6):843-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Patients who had advanced HCC that was not amenable to surgical or regional therapies, up to one prior systemic treatment; Childs-Pugh score A or B liver function; Eastern Cooperative Oncology Group performance status 0, 1, or 2 received B 10 mg/kg every 14 days and E 150 mg orally daily, continuously, for 28-day cycles.
  • RESULTS: The primary end point of PFS16 was 62.5%.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Quinazolines / administration & dosage
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Humanized. Bevacizumab. Drug Therapy, Combination. Erlotinib Hydrochloride. Female. Humans. Male. Middle Aged. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Vascular Endothelial Growth Factor A / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2009 Feb 20;27(6):833-5 [19139428.001]
  • [ErratumIn] J Clin Oncol. 2009 Jul 1;27(19):3263. Lin, Elinor [corrected to Lin, E]
  • (PMID = 19139433.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Quinazolines; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


72. Crowe DR, Eloubeidi MA, Chhieng DC, Jhala NC, Jhala D, Eltoum IA: Fine-needle aspiration biopsy of hepatic lesions: computerized tomographic-guided versus endoscopic ultrasound-guided FNA. Cancer; 2006 Jun 25;108(3):180-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endoscopic ultrasound-guided FNA (EUS-FNA), developed recently and used predominantly in evaluating mediastinal and pancreatic lesions, provides access to a significant portion of the liver and to perihepatic structures not readily accessible by a percutaneous approach.
  • METHODS: A recent experience (1997-2002) with CT-guided FNA of liver lesions at the University of Alabama Birmingham (UAB) was compared with the first 2.5 years of EUS-FNA experience (2000-2002).
  • RESULTS: In 6 years, 34 percutaneous CT-FNA liver biopsies were performed at UAB; in approximately 2.5 years, 16 EUS-FNA liver biopsies were done.
  • In both groups the primary clinical indication was suspected metastatic carcinoma (CT, 41% of cases vs. EUS, 56%).
  • Anatomy limits EUS-FNA to only a fraction of the hepatic parenchyma, but that fraction includes the hilum and left lobe of the liver and the proximal biliary tract.
  • [MeSH-major] Adenocarcinoma / pathology. Endosonography. Liver Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / radiography. Carcinoma, Hepatocellular / ultrasonography. Carcinoma, Neuroendocrine / pathology. Carcinoma, Neuroendocrine / radiography. Carcinoma, Neuroendocrine / ultrasonography. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiography. Carcinoma, Squamous Cell / ultrasonography. Cholangiocarcinoma / pathology. Cholangiocarcinoma / radiography. Cholangiocarcinoma / ultrasonography. Female. Humans. Liver / pathology. Liver / radiography. Liver / ultrasonography. Male. Middle Aged. Tomography, X-Ray Computed


73. Akiyoshi T, Oya M, Fujimoto Y, Kuroyanagi H, Ueno M, Yamaguchi T, Koyama M, Tanaka H, Matsueda K, Muto T: Comparison of preoperative whole-body positron emission tomography with MDCT in patients with primary colorectal cancer. Colorectal Dis; 2009 Jun;11(5):464-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of preoperative whole-body positron emission tomography with MDCT in patients with primary colorectal cancer.
  • OBJECTIVE: Preoperative use of emission tomography with(18)F-fluorodeoxyglucose (FDG-PET) in patients with primary colorectal cancer remains controversial.
  • This study evaluated the additional value of FDG-PET in comparison with routine multidetector row computed tomography (MDCT) in patients with primary colorectal cancer.
  • METHOD: Retrospective analysis was performed in 65 patients with colorectal cancer who underwent whole-body FDG-PET.
  • Results of FDG-PET were compared with routine preoperative evaluation by MDCT regarding detection of primary tumour, lymph node involvement and distant metastases.
  • Liver metastases were present in 22 patients.
  • CONCLUSION: Preoperative FDG-PET is not superior to MDCT for detection of primary tumour, lymph node involvement or liver metastases, but may have potential clinical value in patients with advanced colorectal cancer by detecting extrahepatic distant metastases.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Fluorodeoxyglucose F18. Humans. Liver Neoplasms / radiography. Liver Neoplasms / radionuclide imaging. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Radiopharmaceuticals. Retrospective Studies. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18637927.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


74. Reyes DK, Vossen JA, Kamel IR, Azad NS, Wahlin TA, Torbenson MS, Choti MA, Geschwind JF: Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States. Cancer J; 2009 Nov-Dec;15(6):526-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Twenty patients with unresectable HCC (75% Child's A, 95% Eastern Cooperative Oncology Group performance status 0 to 1, 60% Barcelona Clinic Liver Cancer C, tumor size 6.9 cm) underwent 34 DEB-TACE sessions.
  • Primary endpoints were tumor response, assessed by contrast-enhanced magnetic resonance imaging at 1 month after treatment, using size (response evaluation criteria in solid tumors [RECIST]), contrast-enhancement (European Association for the Study of the Liver) and apparent diffusion coefficient values, and safety assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE).
  • By European Association for the Study of the Liver criteria, 12 patients (60%) had objective tumor response, and 8 (40%) had stable disease.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic. Doxorubicin / administration & dosage. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibiotics, Antineoplastic / administration & dosage. Antibiotics, Antineoplastic / adverse effects. Antibiotics, Antineoplastic / therapeutic use. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Linear Models. Magnetic Resonance Imaging. Male. Microspheres. Middle Aged. Multivariate Analysis. Pilot Projects. Proportional Hazards Models. Prospective Studies. Treatment Outcome. United States

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20010173.001).
  • [ISSN] 1540-336X
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA006973
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 80168379AG / Doxorubicin
  • [Other-IDs] NLM/ NIHMS433720; NLM/ PMC4390059
  •  go-up   go-down


75. Buchler T, Freeman A, Harland S: Contralateral intratubular germ cell neoplasia in a patient with testicular cancer. Nat Clin Pract Urol; 2008 May;5(5):284-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contralateral intratubular germ cell neoplasia in a patient with testicular cancer.
  • INVESTIGATIONS: Measurement of serum levels of urea, electrolytes, liver enzymes, bilirubin, human chorionic gonadotropin, alpha-fetoprotein, lactate dehydrogenase, testosterone and luteinizing hormone, full blood count, and left testicular biopsy.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / pathology. Neoplasms, Multiple Primary / pathology. Seminiferous Tubules / pathology. Seminoma / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Androgens / therapeutic use. Antineoplastic Agents / therapeutic use. Atrophy. Carboplatin / therapeutic use. Humans. Hypogonadism / diagnosis. Hypogonadism / therapy. Male. Orchiectomy. Testis / pathology. Testis / surgery. Testosterone / therapeutic use

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18398407.001).
  • [ISSN] 1743-4289
  • [Journal-full-title] Nature clinical practice. Urology
  • [ISO-abbreviation] Nat Clin Pract Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgens; 0 / Antineoplastic Agents; 3XMK78S47O / Testosterone; BG3F62OND5 / Carboplatin
  •  go-up   go-down


76. Imataki O, Makimoto A, Kojima R, Sakiyama M, Hosono A, Takaue Y: Intensive multimodality therapy including paclitaxel and reduced-intensity allogeneic hematopoietic stem cell transplantation in the treatment of adrenal cancer with multiple metastases. Int J Clin Oncol; 2006 Apr;11(2):156-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive multimodality therapy including paclitaxel and reduced-intensity allogeneic hematopoietic stem cell transplantation in the treatment of adrenal cancer with multiple metastases.
  • Although she underwent surgical resection of the extensive tumor as the primary treatment, the disease recurred in the lung and liver as multiple metastases shortly after surgery.
  • She received intensive multimodality therapy, including chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP regimen), embolization of the feeding arteries, and proton irradiation for the liver mass.
  • [MeSH-major] Adrenal Gland Neoplasms / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Liver Neoplasms / therapy. Lung Neoplasms / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Fatal Outcome. Female. Graft vs Host Disease. Humans


77. Nasir A, Stridsberg M, Strosberg J, Su PH, Livingston S, Malik HA, Kelley ST, Centeno BA, Coppola D, Malafa ME, Yeatman TJ, Kvols LK: Somatostatin receptor profiling in hepatic metastases from small intestinal and pancreatic neuroendocrine neoplasms: immunohistochemical approach with potential clinical utility. Cancer Control; 2006 Jan;13(1):52-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We retrospectively studied SSTR subtype expression in hepatic metastases from 14 adult patients with primary endocrine carcinomas (ECAs) of the small intestine and pancreas and compared SSTR subtype expression among the primary and metastatic ECAs.
  • Polyclonal antibodies against the 5 SSTR subtypes were used on formalin-fixed, paraffin sections from each primary and metastatic ECA.
  • We also observed the immunohistochemical evidence of heterogeneity of expression of various SSTR subtypes in the primary enteropancreatic ECAs and their hepatic metastases.
  • [MeSH-major] Carcinoma, Neuroendocrine / secondary. Intestinal Neoplasms / metabolism. Liver Neoplasms / secondary. Pancreatic Neoplasms / metabolism. Receptors, Somatostatin / metabolism. Somatostatin / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16508627.001).
  • [ISSN] 1073-2748
  • [Journal-full-title] Cancer control : journal of the Moffitt Cancer Center
  • [ISO-abbreviation] Cancer Control
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Somatostatin; 51110-01-1 / Somatostatin
  •  go-up   go-down


78. Abu Hilal M, Underwood T, Zuccaro M, Primrose J, Pearce N: Short- and medium-term results of totally laparoscopic resection for colorectal liver metastases. Br J Surg; 2010 Jun;97(6):927-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short- and medium-term results of totally laparoscopic resection for colorectal liver metastases.
  • BACKGROUND: Laparoscopic surgery for primary colorectal cancer is now commonplace but the uptake of laparoscopic surgery for colorectal liver metastasis (CRLM) has been slow, mainly owing to doubts regarding safety, feasibility and oncological efficiency.
  • RESULTS: Over 5 years, 135 patients underwent liver surgery for CRLM.
  • [MeSH-major] Colorectal Neoplasms. Laparoscopy / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Length of Stay. Male. Middle Aged. Prospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20474003.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


79. Krasna MJ, Gamliel Z, Burrows WM, Sonett JR, Kwong KF, Edelman MJ, Hausner PF, Doyle LA, DeYoung C, Suntharalingam M: Pneumonectomy for lung cancer after preoperative concurrent chemotherapy and high-dose radiation. Ann Thorac Surg; 2010 Jan;89(1):200-6; discussion 206
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pneumonectomy for lung cancer after preoperative concurrent chemotherapy and high-dose radiation.
  • BACKGROUND: We studied the clinical characteristics and outcomes of patients undergoing pneumonectomy after preoperative concurrent chemoradiation for non-small cell lung cancer.
  • METHODS: Clinical records of patients with non-small cell lung cancer who underwent pneumonectomy at our institution between 1995 and 2005 after preoperative concurrent chemoradiation were reviewed retrospectively.
  • Of the 21 men and 8 women who were treated, 1 had stage IIB (T3N0M0) and the remainder had stage IIIA or IIIB non-small cell lung cancer.
  • Recurrences have been found in 11 patients (38%), including brain metastases (n = 6), bone metastases (n = 4), liver metastases (n = 2), and cervical lymph node metastases (n = 2).
  • One patient had a contralateral new primary lung cancer develop 70 months after undergoing pneumonectomy.
  • The frequency of disease recurrence in the brain underscores the need to evaluate the role of prophylactic cranial radiation in non-small cell lung cancer.
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Radiation Dosage. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20103235.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


80. Janković J, Ratkov I, Sipetić S, Marinković J, Maksimović J: [Oesophageal-cancer-derived death in the population of Belgrade in a period 1989-2006]. Vojnosanit Pregl; 2009 Jul;66(7):534-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Oesophageal-cancer-derived death in the population of Belgrade in a period 1989-2006].
  • BACKGROUND/AIM: Oesophageal cancer is the sixth most common cause of death from all malignant tumors in the world (fifth in men, eighth in women).
  • This cancer was estimated to account for about 529 000 new cases and about 442 000 deaths in the year 2007.
  • The aim of this descriptive epidemiologic study was to analyze epidemiologic situation of oesophageal cancer in Belgrade population during the period 1989-2006, using mortality data.
  • In order to analyze trend mortality from oesophageal cancer we used linear trend.
  • RESULTS: In Belgrade deaths from oesophageal cancer accounted for about 5.2% of all malignant tumors of intestinal system in male population, and 2.4% in female population.
  • This cancer is, according to standardized mortality rates (per 100 000 habitants), on the fifth place in Belgrade population behind colorectal, stomach, pancreatic, liver and cholecystic cancer.
  • The male/female oesophageal cancer mortality ratio was 3:1.
  • Mortality rates for oesophageal cancer rise with age in both sexes and they are highest in the age group of 70 and more years.
  • Significant increase in mortality from oesophageal cancer was noticed in age groups 20-29 and over 70 in male population, and age group 40-49 in female population.
  • CONCLUSION: Increasing trend in oesophageal mortality suggests the necessity for improving measures of primary prevention including education about risk factors for this carcinoma (smoking, alcohol consumption, hot food and drinks), early diagnosis, and treatment.
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Serbia / epidemiology. Young Adult

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19678577.001).
  • [ISSN] 0042-8450
  • [Journal-full-title] Vojnosanitetski pregled
  • [ISO-abbreviation] Vojnosanit Pregl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


81. Kotb HI, Fouad IA, Fares KM, Mostafa MG, Abd El-Rahman AM: Pharmacokinetics of oral tramadol in patients with liver cancer. J Opioid Manag; 2008 Mar-Apr;4(2):99-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacokinetics of oral tramadol in patients with liver cancer.
  • BACKGROUND: There are no studies reported on pharmacokinetics of opioids in patients with hepatocellular carcinoma, the fifth most common cancer in the world.
  • METHODS: The authors have studied the pharmacokinetic profile of oral tramadol (50 mg) capsule in 20 patients with liver carcinoma (10 with primary carcinoma on top of chronic hepatitis C and 10 with secondary metastatic liver malignancy as a result of other primary) compared with 10 healthy controls.
  • RESULTS: Tramadol bioavailability showed a substantial increase in patients with primary liver cancer and secondary metastatic than that of control (98 percent, 75 percent, and 68 percent, respectively).
  • The area under the serum concentration-time curve increased significantly in patients with primary and metastatic cancer of liver than in control [1,933 microg/h/L (SD = 41), 1,327 microg/h/L (SD = 51), 1,138.5 microg/h/L (SD = 31), respectively].
  • Also, a significant difference in Cmax and Tmax was found between patients with malignant liver and control.
  • Reduced clearance and impaired elimination was significantly observed in patients with liver carcinoma than control.
  • Clearance was reduced to 50 percent of control, and elimination halflife increased up to three folds in patients with primary liver carcinoma than that of control.
  • CONCLUSION: It is recommended to lengthen the dose interval of oral tramadol, if it is to be used in patients with liver cancer for analgesic purposes, to 50 mg every 12 hours as it is proved to be effective and safe.
  • [MeSH-major] Analgesics, Opioid / pharmacokinetics. Liver Neoplasms / physiopathology. Pain, Intractable / drug therapy. Tramadol / pharmacokinetics
  • [MeSH-minor] Adult. Aged. Biological Availability. Humans. Metabolic Clearance Rate. Middle Aged. Prospective Studies

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18557166.001).
  • [ISSN] 1551-7489
  • [Journal-full-title] Journal of opioid management
  • [ISO-abbreviation] J Opioid Manag
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 39J1LGJ30J / Tramadol
  •  go-up   go-down


82. Vrettou E, Hytiroglou P, Sikas N, Soultoyannis I, Goodman ZD: Hepatic adenocarcinoma expressing inhibin in a young patient on oral contraceptives. Virchows Arch; 2005 May;446(5):560-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A case of primary hepatic carcinoma is reported, which occurred in a 24-year-old woman with a 10-year history of oral contraceptive use, and demonstrated unique morphologic and immunohistochemical features.
  • [MeSH-major] Adenocarcinoma / diagnosis. Contraceptives, Oral, Combined / administration & dosage. Inhibins / analysis. Liver Neoplasms / diagnosis
  • [MeSH-minor] Abdominal Pain. Adult. CA-19-9 Antigen / analysis. Carcinoembryonic Antigen / analysis. Female. Humans. Immunohistochemistry. Keratin-7. Keratins / analysis. Magnetic Resonance Imaging. Nausea. Tomography, X-Ray Computed. Vomiting

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 1998 Jul;11(7):656-64 [9688187.001]
  • [Cites] Cancer. 1987 Jun 15;59(12):2112-6 [3567872.001]
  • [Cites] Mod Pathol. 1998 Jun;11(6):516-24 [9647588.001]
  • [Cites] Int J Gynecol Pathol. 1999 Apr;18(2):144-50 [10202672.001]
  • [Cites] Mod Pathol. 1998 Dec;11(12):1160-4 [9872645.001]
  • [Cites] Am J Clin Pathol. 1999 Feb;111(2):229-34 [9930145.001]
  • [Cites] Mod Pathol. 2003 Jun;16(6):591-7 [12808065.001]
  • [Cites] Hum Pathol. 2002 Dec;33(12):1175-81 [12514785.001]
  • [Cites] Hepatology. 2001 Jun;33(6):1387-93 [11391527.001]
  • [Cites] Cancer. 1991 Nov 1;68(9):2051-5 [1717133.001]
  • (PMID = 15815932.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; 0 / Contraceptives, Oral, Combined; 0 / KRT7 protein, human; 0 / Keratin-7; 57285-09-3 / Inhibins; 68238-35-7 / Keratins
  •  go-up   go-down


83. Lepistö A, Kärkkäinen P, Järvinen HJ: Prevalence of primary sclerosing cholangitis in ulcerative colitis patients undergoing proctocolectomy and ileal pouch-anal anastomosis. Inflamm Bowel Dis; 2008 Jun;14(6):775-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of primary sclerosing cholangitis in ulcerative colitis patients undergoing proctocolectomy and ileal pouch-anal anastomosis.
  • BACKGROUND: This study aimed to determine the prevalence of primary sclerosing cholangitis (PSC) among patients with ulcerative colitis (UC) needing proctocolectomy.
  • Liver biopsy samples were taken at operation.
  • Only 19 of these had been diagnosed before surgery; 40 patients with PSC were detected by liver biopsy at the operation, making the sensitivity of perioperative liver biopsy to diagnose PSC 83.3%.
  • The cumulative incidence of colorectal dysplasia or cancer in the UC patients with PSC (19% after 10 years and 43% after 20 years) was not significantly different than that of UC patients without PSC (24% after 10 years and 39% after 20 years).
  • Liver biopsy can be recommended as a safe adjunct at proctocolectomy for surveillance of any liver effects.
  • [MeSH-minor] Adolescent. Adult. Aged. Anal Canal / surgery. Bile Duct Neoplasms / etiology. Bile Ducts, Intrahepatic. Biopsy. Cholangiocarcinoma / etiology. Female. Humans. Liver / pathology. Liver Transplantation. Male. Middle Aged. Pouchitis / etiology. Prevalence. Treatment Failure


84. Gaj P, Habior A, Mikula M, Ostrowski J: Lack of evidence for association of primary sclerosing cholangitis and primary biliary cirrhosis with risk alleles for Crohn's disease in Polish patients. BMC Med Genet; 2008;9:81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of evidence for association of primary sclerosing cholangitis and primary biliary cirrhosis with risk alleles for Crohn's disease in Polish patients.
  • We investigated whether polymorphisms that confer susceptibility to Crohn's disease could be classified also as predisposing factors for the development of primary sclerosing cholangitis and primary biliary cirrhosis in Polish patients.
  • In contrast, none of the polymorphisms exhibited association with susceptibility to primary sclerosing cholangitis and primary biliary cirrhosis, including a group of primary sclerosing cholangitis patients with concurrent IBD.
  • CONCLUSION: Although the clinical data indicate non-random co-occurrence of inflammatory bowel disease and primary sclerosing cholangitis, consistently with the previously published studies, no genetic association was found between the genetic variants predisposing to Crohn's disease and hepatobiliary autoimmune disorders.
  • [MeSH-major] Cholangitis, Sclerosing / genetics. Crohn Disease / genetics. Genetic Predisposition to Disease. Liver Cirrhosis, Biliary / genetics
  • [MeSH-minor] Adult. Aged. Alleles. Chi-Square Distribution. Female. Gene Frequency. Genetic Markers. Genotype. Humans. Male. Middle Aged. Poland. Polymorphism, Single Nucleotide. Risk Factors


85. Nagata S, Aishima S, Fukuzawa K, Takagi H, Yonemasu H, Iwashita Y, Kinoshita T, Wakasugi K: Adenomatoid tumour of the liver. J Clin Pathol; 2008 Jun;61(6):777-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenomatoid tumour of the liver.
  • An unusual primary adenomatoid tumour arising in the normal liver is described.
  • [MeSH-major] Adenomatoid Tumor / pathology. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Calbindin 2. Hepatectomy. Humans. Immunohistochemistry. Keratins / analysis. Male. Neovascularization, Pathologic. S100 Calcium Binding Protein G / analysis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2003 Jun;16(6):613-7 [12808068.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):969-77 [12826889.001]
  • [Cites] Urology. 1975 Nov;6(5):635-41 [1189154.001]
  • [Cites] J Pathol. 1986 Apr;148(4):327-35 [3517266.001]
  • [Cites] J Clin Pathol. 2007 Jun;60(6):722-4 [17483249.001]
  • [Cites] Cancer. 1999 Feb 1;85(3):562-82 [10091730.001]
  • [Cites] J Clin Ultrasound. 2005 Jun;33(5):233-6 [16047378.001]
  • [Cites] Scand J Gastroenterol Suppl. 2006;(243):102-15 [16782629.001]
  • [Cites] Curr Probl Diagn Radiol. 2007 May-Jun;36(3):107-23 [17484954.001]
  • [Cites] Am J Surg Pathol. 1996 Oct;20(10):1219-23 [8827028.001]
  • (PMID = 18505892.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / S100 Calcium Binding Protein G; 68238-35-7 / Keratins
  • [Other-IDs] NLM/ PMC2569191
  •  go-up   go-down


86. Harzke AJ, Baillargeon JG, Goodman KJ, Pruitt SL: Liver cancer mortality among male prison inmates in Texas, 1992-2003. Prev Med; 2009 Jun;48(6):588-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver cancer mortality among male prison inmates in Texas, 1992-2003.
  • OBJECTIVES: Prevalence estimates for several liver cancer risk factors-hepatitis C, hepatitis B, and history of alcohol abuse-are substantially higher in U.S. prison populations than in the general population.
  • However, liver cancer mortality data from these populations are lacking.
  • The primary aims of this study were to examine trends in liver cancer mortality rates from 1992 to 2003 among male prisoners in the Texas Department of Criminal Justice (TDCJ) and to compare these rates to general population rates.
  • Crude average annual liver cancer death rates, average annual percent changes, and standardized mortality ratios were estimated.
  • RESULTS: Crude liver cancer death rates increased by an average annual 6.1% among male prisoners, which was considerably higher than the average annual percent change among similarly aged males in Texas (2.0%) and the U.S. (2.9%).
  • The number of liver cancer deaths among male prisoners was 4.7 (4.0-5.6) and 6.3 (5.3-7.5) times higher than the expected number of deaths estimated using age-specific rates from these reference populations.
  • CONCLUSIONS: From 1992 to 2003, liver cancer death rates and rate increases were elevated among Texas male prisoners.
  • Findings support previous recommendations for targeted prevention, screening, and treatment of liver cancer risk factors in prison populations.

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Aug 19;341(8):556-62 [10451460.001]
  • [Cites] Alcohol Alcohol. 1995 Mar;30(2):177-86 [7662036.001]
  • [Cites] Am J Epidemiol. 1990 Feb;131(2):373-5 [2296988.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2004 Aug 6;53(30):681-3 [15295312.001]
  • [Cites] JAMA. 2004 Jul 28;292(4):423-4 [15280325.001]
  • [Cites] Am J Public Health. 2004 Jul;94(7):1218-23 [15226146.001]
  • [Cites] Drug Alcohol Depend. 2004 Jun 11;74(3):223-34 [15194200.001]
  • [Cites] J Urban Health. 2004 Mar;81(1):25-37 [15047781.001]
  • [Cites] Ann Intern Med. 2003 Nov 18;139(10):817-23 [14623619.001]
  • [Cites] JAMA. 2003 Jul 9;290(2):228-37 [12851278.001]
  • [Cites] Public Health. 2003 Jan;117(1):43-8 [12802904.001]
  • [Cites] JAMA. 2003 Jun 4;289(21):2849-56 [12783916.001]
  • [Cites] MMWR Recomm Rep. 2003 Jan 24;52(RR-1):1-36; quiz CE1-4 [12562146.001]
  • [Cites] Vaccine. 2002 Dec 13;21(3-4):312-21 [12450707.001]
  • [Cites] AIDS. 2002 Nov 8;16(16):2236-8 [12409752.001]
  • [Cites] Arch Intern Med. 2000 Nov 27;160(21):3227-30 [11088082.001]
  • [Cites] Public Health Rep. 2009 Jan-Feb;124(1):120-6 [19413034.001]
  • [Cites] Am J Public Health. 2000 Jan;90(1):139-40 [10630155.001]
  • [Cites] Am J Public Health. 2008 Dec;98(12):2278-84 [18923131.001]
  • [Cites] Hepatology. 2008 Nov;48(5):1387-95 [18924228.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1198-203 [16775181.001]
  • [Cites] Ann Intern Med. 2006 May 16;144(10):762-9 [16702592.001]
  • [Cites] Ann Intern Med. 2006 May 16;144(10):705-14 [16702586.001]
  • [Cites] Addiction. 2006 Feb;101(2):181-91 [16445547.001]
  • [Cites] Cancer. 2005 Nov 15;104(10):2197-204 [16206295.001]
  • (PMID = 19289141.001).
  • [ISSN] 1096-0260
  • [Journal-full-title] Preventive medicine
  • [ISO-abbreviation] Prev Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA057712-14; United States / NCI NIH HHS / CA / R25 CA057712; United States / NCI NIH HHS / CA / R25 CA 57712; United States / NCI NIH HHS / CA / R25 CA057712-14
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS190514; NLM/ PMC2879635
  •  go-up   go-down


87. Chitapanarux I, Chitapanarux T, Traisathit P, Kudumpee S, Tharavichitkul E, Lorvidhaya V: Randomized controlled trial of live lactobacillus acidophilus plus bifidobacterium bifidum in prophylaxis of diarrhea during radiotherapy in cervical cancer patients. Radiat Oncol; 2010;5:31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized controlled trial of live lactobacillus acidophilus plus bifidobacterium bifidum in prophylaxis of diarrhea during radiotherapy in cervical cancer patients.
  • This study was performed to determine the ability of a probiotic containing live lactobacillus acidophilus plus bifidobacterium bifidum to reduce the incidence of radiation-induced diarrhea in locally advanced cervical cancer patients.
  • The primary endpoint was to reduce the incidence of diarrhea, defined by a CTC grade 2 or more, and the need for anti-diarrheal medication.
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Aged. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Double-Blind Method. Female. Humans. Incidence. Middle Aged. Pelvic Neoplasms / pathology. Pelvic Neoplasms / radiotherapy. Placebos. Probiotics / therapeutic use. Prospective Studies. Radiation Injuries / etiology. Radiation Injuries / prevention & control. Treatment Outcome. Young Adult


88. Liu J, Xie Y, Ducharme DM, Shen J, Diwan BA, Merrick BA, Grissom SF, Tucker CJ, Paules RS, Tennant R, Waalkes MP: Global gene expression associated with hepatocarcinogenesis in adult male mice induced by in utero arsenic exposure. Environ Health Perspect; 2006 Mar;114(3):404-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Global gene expression associated with hepatocarcinogenesis in adult male mice induced by in utero arsenic exposure.
  • Our previous work has shown that exposure to inorganic arsenic in utero produces hepatocellular carcinoma (HCC) in adult male mice.
  • The incidence of HCC in adult male offspring was increased 4-fold and tumor multiplicity 3-fold after transplacental arsenic exposure.
  • Samples of normal liver and liver tumors were taken at autopsy for genomic analysis.
  • Arsenic exposure in utero resulted in significant alterations (p < 0.001) in the expression of 2,010 genes in arsenic-exposed liver samples and in the expression of 2,540 genes in arsenic-induced HCC.
  • Ingenuity Pathway Analysis revealed that significant alterations in gene expression occurred in a number of biological networks, and Myc plays a critical role in one of the primary networks.
  • Liver feminization was evidenced by increased expression of estrogen-linked genes and altered expression of genes that encode gender-related metabolic enzymes.

  • MedlinePlus Health Information. consumer health - Arsenic.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Carcinog. 2001 Feb;30(2):79-87 [11241755.001]
  • [Cites] Toxicol Appl Pharmacol. 2005 Aug 15;206(3):288-98 [16039940.001]
  • [Cites] Toxicol Sci. 2001 Jun;61(2):314-20 [11353140.001]
  • [Cites] Anticancer Res. 2001 Mar-Apr;21(2B):1339-45 [11396210.001]
  • [Cites] Toxicol Appl Pharmacol. 2000 Apr 15;164(2):161-70 [10764629.001]
  • [Cites] Toxicol Sci. 2000 Jun;55(2):460-7 [10828279.001]
  • [Cites] Environ Health Perspect. 2000 Jun;108 Suppl 3:573-94 [10852857.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3445-53 [10910055.001]
  • [Cites] Environ Health Perspect. 2000 Jul;108(7):655-61 [10903620.001]
  • [Cites] J Toxicol Clin Toxicol. 2000;38(4):395-405 [10930056.001]
  • [Cites] Toxicol Sci. 2001 Jan;59(1):185-92 [11134558.001]
  • [Cites] Cancer Res. 2001 Jul 15;61(14):5389-95 [11454681.001]
  • [Cites] Mol Pharmacol. 2001 Aug;60(2):302-9 [11455017.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 Sep 15;175(3):260-8 [11559025.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 Oct 1;176(1):64-71 [11578149.001]
  • [Cites] Environ Health Perspect. 2002 Feb;110(2):119-22 [11836136.001]
  • [Cites] Toxicol Lett. 2002 Mar 10;128(1-3):73-84 [11869819.001]
  • [Cites] Carcinogenesis. 2002 May;23(5):777-85 [12016150.001]
  • [Cites] Int J Cancer. 2002 Jun 10;99(5):629-34 [12115494.001]
  • [Cites] Carcinogenesis. 2002 Aug;23(8):1387-97 [12151359.001]
  • [Cites] Alcohol. 2002 Jul;27(3):155-62 [12163143.001]
  • [Cites] Environ Health Perspect. 2002 Oct;110 Suppl 5:883-6 [12426152.001]
  • [Cites] Toxicol Appl Pharmacol. 2003 Jan 1;186(1):7-17 [12583988.001]
  • [Cites] Carcinogenesis. 2003 Apr;24(4):757-70 [12727805.001]
  • [Cites] Exp Cell Res. 2003 Nov 1;290(2):234-45 [14567983.001]
  • [Cites] Carcinogenesis. 2004 Jan;25(1):133-41 [14514661.001]
  • [Cites] Horm Metab Res. 2003 Nov-Dec;35(11-12):685-93 [14710347.001]
  • [Cites] Toxicol Pathol. 2004 Jan-Feb;32(1):64-72 [14713550.001]
  • [Cites] Toxicol Sci. 2004 Feb;77(2):249-57 [14691202.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):466-74 [15026472.001]
  • [Cites] Am J Public Health. 2004 May;94(5):741-4 [15117692.001]
  • [Cites] J Biol Chem. 2004 Jul 30;279(31):32700-8 [15161912.001]
  • [Cites] Carcinogenesis. 2004 Sep;25(9):1779-86 [15073043.001]
  • [Cites] Lab Invest. 2004 Sep;84(9):1137-47 [15220935.001]
  • [Cites] Environ Health Perspect. 2004 Aug;112(12):1255-63 [15345372.001]
  • [Cites] J Toxicol Environ Health A. 2004 Oct 8;67(19):1491-500 [15371225.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum Suppl. 1987;7:1-440 [3482203.001]
  • [Cites] J Hyg Epidemiol Microbiol Immunol. 1988;32(2):137-46 [2457611.001]
  • [Cites] J Pharmacol Exp Ther. 1996 May;277(2):1026-33 [8627513.001]
  • [Cites] J Gastroenterol Hepatol. 1997 Oct;12(9-10):S294-308 [9407350.001]
  • [Cites] Mol Cell Biol. 1998 Aug;18(8):4499-508 [9671459.001]
  • [Cites] Toxicol Sci. 1998 Aug;44(2):185-90 [9742656.001]
  • [Cites] Am J Pathol. 1998 Dec;153(6):1775-85 [9846968.001]
  • [Cites] World J Gastroenterol. 2004 Dec 1;10(23):3414-8 [15526358.001]
  • [Cites] Int J Oncol. 2005 Feb;26(2):369-77 [15645121.001]
  • [Cites] FEBS J. 2005 Jan;272(2):413-21 [15654879.001]
  • [Cites] Oncogene. 2005 Mar 10;24(11):1831-46 [15674350.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8644-9 [15937110.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 May 1;172(3):249-61 [11312654.001]
  • (PMID = 16507464.001).
  • [ISSN] 0091-6765
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / N01CO12400; United States / NCI NIH HHS / CO / N01-CO-12400; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] N712M78A8G / Arsenic
  • [Other-IDs] NLM/ PMC1392235
  •  go-up   go-down


89. Zhang ZY, King BM, Pelletier RD, Wong YN: Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4. Cancer Chemother Pharmacol; 2008 Sep;62(4):707-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eribulin is currently in Phase III clinical trials for the treatment of metastatic breast cancer.
  • METHODS: Identification of the enzyme(s) responsible for eribulin metabolism was based on compound depletion and metabolite formation in reaction mixtures containing subcellular liver fractions or primary human hepatocytes, plus recombinant Phases I and II metabolic enzymes.
  • The effect of eribulin on enzymatic activity was characterized using both microsomal preparations and recombinant enzymes, while the possible modulation of protein expression was evaluated in primary cultures of human hepatocytes.
  • In human liver microsomal preparations, eribulin suppressed the activities of CYP3A4-mediated testosterone and midazolam hydroxylation with an apparent K (i) of approximately 20 microM.
  • Eribulin did not induce the expression or activities of CYP1A and CYP3A enzymes in human primary hepatocytes, and clinically relevant concentrations of eribulin did not inhibit CYP3A4-mediated metabolism of various therapeutic agents, including carbamazepine, diazepam, paclitaxel, midazolam, tamoxifen, or terfenadine.
  • [MeSH-minor] Adult. Aged. Cells, Cultured. Child. Child, Preschool. Cytochrome P-450 CYP3A Inhibitors. Dose-Response Relationship, Drug. Drug Interactions. Female. Humans. Infant, Newborn. Male. Microsomes, Liver / drug effects. Microsomes, Liver / metabolism. Middle Aged. Nifedipine / metabolism. Recombinant Proteins. Testosterone / metabolism. Warfarin / metabolism

  • Hazardous Substances Data Bank. Nifedipine .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • Hazardous Substances Data Bank. WARFARIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18431572.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cytochrome P-450 CYP3A Inhibitors; 0 / Enzyme Inhibitors; 0 / Furans; 0 / Ketones; 0 / Recombinant Proteins; 0 / eribulin; 3XMK78S47O / Testosterone; 5Q7ZVV76EI / Warfarin; EC 1.14.13.67 / CYP3A4 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP3A; I9ZF7L6G2L / Nifedipine
  •  go-up   go-down


90. Jackson H, Solaymani-Dodaran M, Card TR, Aithal GP, Logan R, West J: Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study. Hepatology; 2007 Oct;46(4):1131-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study.
  • There is debate over the mortality and malignancy risk in people with primary biliary cirrhosis (PBC) and whether this risk is reduced by use of ursodeoxycholic acid.
  • The increased risk of primary liver cancer in ursodeoxycholic acid-treated patients was 3-fold (HR, 3.17; 95% CI, 0.64-15.62), in contrast to an 8-fold increase in those not treated (HR, 7.77; 95% CI, 1.30-46.65).
  • [MeSH-major] Cholagogues and Choleretics / therapeutic use. Liver Cirrhosis, Biliary / drug therapy. Liver Cirrhosis, Biliary / mortality. Liver Neoplasms / epidemiology. Ursodeoxycholic Acid / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Cohort Studies. Female. Humans. Kaplan-Meier Estimate. Longitudinal Studies. Male. Middle Aged. Odds Ratio. Risk Factors. Severity of Illness Index. United Kingdom / epidemiology

  • Genetic Alliance. consumer health - Primary biliary cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hepatology. 2008 Apr;47(4):1428 [18366110.001]
  • [CommentIn] Hepatology. 2007 Oct;46(4):963-5 [17894325.001]
  • (PMID = 17685473.001).
  • [ISSN] 0270-9139
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Grant] United Kingdom / Department of Health / / DHCS/05/05/25
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cholagogues and Choleretics; 724L30Y2QR / Ursodeoxycholic Acid
  •  go-up   go-down


91. Overton ET, Kang M, Peters MG, Umbleja T, Alston-Smith BL, Bastow B, Demarco-Shaw D, Koziel MJ, Mong-Kryspin L, Sprenger HL, Yu JY, Aberg JA: Immune response to hepatitis B vaccine in HIV-infected subjects using granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant: ACTG study 5220. Vaccine; 2010 Aug 02;28(34):5597-604
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary endpoints were quantitative HBsAb titers and adverse events.
  • [MeSH-minor] Adult. Antibody Formation. Female. Hepatitis B / immunology. Hepatitis B / prevention & control. Hepatitis B Antibodies / blood. Humans. Male. Middle Aged. Pilot Projects

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • HIV InSite. treatment guidelines - HIV InSite .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • [Cites] J Viral Hepat. 1999 Sep;6(5):405-9 [10607257.001]
  • [Cites] Vaccine. 2010 Feb 10;28(6):1447-50 [19995540.001]
  • [Cites] Clin Infect Dis. 2001 Feb 1;32(3):492-7 [11170959.001]
  • [Cites] Ren Fail. 2001 Sep;23(5):629-36 [11725909.001]
  • [Cites] Vaccine. 2002 May 31;20 Suppl 3:S18-23 [12184360.001]
  • [Cites] Lancet. 2002 Dec 14;360(9349):1921-6 [12493258.001]
  • [Cites] Vaccine. 2003 Nov 7;21(31):4545-9 [14575766.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6337-43 [15342423.001]
  • [Cites] J Acquir Immune Defic Syndr. 1991;4 Suppl 1:S22-8 [1848618.001]
  • [Cites] J Clin Oncol. 1991 Jun;9(6):929-40 [2033429.001]
  • [Cites] J Clin Gastroenterol. 1992 Jan;14(1):27-30 [1532609.001]
  • [Cites] AIDS. 1992 May;6(5):509-10 [1535502.001]
  • [Cites] Ann Intern Med. 1993 Feb 15;118(4):298-306 [8420448.001]
  • [Cites] AIDS. 1994 Apr;8(4):558-9 [7912087.001]
  • [Cites] J Viral Hepat. 1996 May;3(3):149-53 [8871874.001]
  • [Cites] Am J Med. 1997 Sep;103(3):217-22 [9316554.001]
  • [Cites] Cancer J Sci Am. 1997 Sep-Oct;3(5):278-83 [9327151.001]
  • [Cites] Curr Opin Hematol. 1995 May;2(3):227-33 [9372000.001]
  • [Cites] Vaccine. 1998 Dec;16(20):1933-5 [9796046.001]
  • [Cites] Clin Microbiol Rev. 1999 Apr;12(2):351-66 [10194463.001]
  • [Cites] AIDS. 1999 Apr 16;13(6):633-43 [10397557.001]
  • [Cites] Vaccine. 2005 Apr 22;23(22):2902-8 [15780739.001]
  • [Cites] Clin Infect Dis. 2005 Oct 1;41(7):1045-8 [16142673.001]
  • [Cites] Liver Transpl. 2005 Oct;11(10):1228-34 [16184571.001]
  • [Cites] AIDS. 2005 Dec 2;19(18):2117-25 [16284461.001]
  • [Cites] J Hepatol. 2006;44(1 Suppl):S6-9 [16352363.001]
  • [Cites] Vaccine. 2007 Jan 8;25(4):709-18 [16963165.001]
  • [Cites] HIV Med. 2008 Feb;9(2):82-8 [18257771.001]
  • [Cites] AIDS. 2008 Jul 31;22(12):1399-410 [18614862.001]
  • [Cites] MMWR Recomm Rep. 2009 Apr 10;58(RR-4):1-207; quiz CE1-4 [19357635.001]
  • [Cites] Vaccine. 2009 Jul 23;27(34):4731-8 [19540026.001]
  • [Cites] Clin Infect Dis. 2009 Sep 1;49(5):651-81 [19640227.001]
  • [Cites] Clin Infect Dis. 2009 Sep 15;49(6):817-40 [19659433.001]
  • [Cites] Clin Nephrol. 2000 Aug;54(2):138-42 [10968690.001]
  • (PMID = 20600512.001).
  • [ISSN] 1873-2518
  • [Journal-full-title] Vaccine
  • [ISO-abbreviation] Vaccine
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / U01 AI069502; United States / NIAID NIH HHS / AI / U01 AI069513; United States / NIAID NIH HHS / AI / UM1 AI069501; United States / NIAID NIH HHS / AI / U01 AI069474; United States / NIAID NIH HHS / AI / UM1 AI069513; United States / NIAID NIH HHS / AI / U01 AI068636-01; United States / NIAID NIH HHS / AI / U01 AI069434; United States / NIAID NIH HHS / AI / U01 AI069532-01; United States / NIAID NIH HHS / AI / AI038855; United States / NCRR NIH HHS / RR / RR 024160; United States / NIAID NIH HHS / AI / U01 AI069495-01; United States / NIAID NIH HHS / AI / AI 69434; United States / NIAID NIH HHS / AI / AI 69471; United States / NIAID NIH HHS / AI / AI 69474; United States / NIAID NIH HHS / AI / AI 69495; United States / NIAID NIH HHS / AI / UM1 AI069434; United States / NIAID NIH HHS / AI / AI 69501; United States / NIAID NIH HHS / AI / AI 69513; United States / NIAID NIH HHS / AI / AI069532; United States / NIAID NIH HHS / AI / U01 AI027665-110001; United States / NIAID NIH HHS / AI / UM1 AI069495; United States / NIAID NIH HHS / AI / AI 69511; United States / NIAID NIH HHS / AI / U01 AI069484; United States / NIAID NIH HHS / AI / UM1 AI069471; United States / NIAID NIH HHS / AI / U01 AI038855; United States / NIAID NIH HHS / AI / U01 AI068634-01; United States / NIAID NIH HHS / AI / U01 AI069532; United States / NIAID NIH HHS / AI / UM1 AI069484; United States / NIAID NIH HHS / AI / UM1 AI068634; United States / NIAID NIH HHS / AI / AI027665; United States / NIAID NIH HHS / AI / U01 AI069501; United States / NIAID NIH HHS / AI / AI069495; United States / NIAID NIH HHS / AI / U01 AI038855-04; United States / NIAID NIH HHS / AI / AI 69484-02; United States / NIAID NIH HHS / AI / U01 AI068636; United States / NIAID NIH HHS / AI / UM1 AI069474; United States / NCRR NIH HHS / RR / UL1 RR024160; United States / NIAID NIH HHS / AI / U01 AI069495; United States / NIAID NIH HHS / AI / AI 68634; United States / NIAID NIH HHS / AI / U01 AI069511; United States / NIAID NIH HHS / AI / UM1 AI069532; United States / NIAID NIH HHS / AI / AI 69532; United States / NIAID NIH HHS / AI / AI 68636; United States / NIAID NIH HHS / AI / AI068634; United States / NIAID NIH HHS / AI / UM1 AI069511; United States / NIAID NIH HHS / AI / U01 AI027665; United States / NIAID NIH HHS / AI / U01 AI069471; United States / NIAID NIH HHS / AI / U01 AI068634; United States / NIAID NIH HHS / AI / UM1 AI068636
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Hepatitis B Antibodies; 0 / Hepatitis B Vaccines; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  • [Other-IDs] NLM/ NIHMS222340; NLM/ PMC2943846
  •  go-up   go-down


92. D'Arrigo A, Belluco C, Ambrosi A, Digito M, Esposito G, Bertola A, Fabris M, Nofrate V, Mammano E, Leon A, Nitti D, Lise M: Metastatic transcriptional pattern revealed by gene expression profiling in primary colorectal carcinoma. Int J Cancer; 2005 Jun 10;115(2):256-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic transcriptional pattern revealed by gene expression profiling in primary colorectal carcinoma.
  • Metastatic spread to the liver is the major contributor to mortality in patients with colorectal carcinoma (CRC).
  • In order to seek for gene expression patterns associated with metastatic potential in primary CRC, we compared the transcriptional profiles of 10 radically resected primary CRCs from patients who did not develop distant metastases within a 5-year follow-up period with those of 10 primary/metastatic tumor pairs from patients with synchronous liver metastases.
  • While a striking transcriptional similarity was observed between the primary tumors and their distant metastases, the nonmetastasizing primary tumors were clearly distinct from the primary/metastatic tumor pairs.
  • Of 37 gene expression differences found between the 2 groups of primary tumors, 29 also distinguished nonmetastasizing tumors from metastases.
  • The gene encoding for mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetyl-glucosaminyl-transferase (GnT-IV) became significantly upregulated in primary/metastatic tumor pairs (p < 0.001).
  • These data support the existence of a specific transcriptional signature distinguishing primary colon adenocarcinomas with different metastatic potential, the further pursuit of which may lead to relevant clinical and therapeutic applications.
  • [MeSH-minor] Adult. Aged. Female. Humans. Lasers. Male. Middle Aged. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Reverse Transcriptase Polymerase Chain Reaction. Transcription, Genetic

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc
  • (PMID = 15688387.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.4.1.- / N-Acetylglucosaminyltransferases; EC 2.4.1.145 / alpha-1,3-mannosylglycoprotein beta-1,4-N-acetylglucosaminyltransferase
  •  go-up   go-down


93. Onken MD, Worley LA, Harbour JW: Association between gene expression profile, proliferation and metastasis in uveal melanoma. Curr Eye Res; 2010 Sep;35(9):857-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: The study included 28 primary uveal melanomas with extensive clinical, pathologic, and genetic annotation, including age, gender, ciliary body involvement, tumor basal diameter, thickness, cell type, gene expression profile, status of chromosomes 3 and 8p, aneuploidy, and clinical outcome.

  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Eye Res. 2006 Jan;31(1):57-67 [16421020.001]
  • [Cites] Am J Ophthalmol. 2005 Oct;140(4):748-9 [16226537.001]
  • [Cites] Clin Cancer Res. 2007 Mar 1;13(5):1466-71 [17332290.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14(1):115-22 [18172260.001]
  • [Cites] Melanoma Res. 2008 Jun;18(3):191-200 [18477893.001]
  • [Cites] Clin Cancer Res. 2008 Jun 15;14(12):3737-45 [18559591.001]
  • [Cites] Nat Rev Cancer. 2009 Mar;9(3):153-66 [19238148.001]
  • [Cites] Ophthalmology. 2001 Feb;108(2):367-71 [11158814.001]
  • [Cites] Curr Eye Res. 2002 Feb;24(2):105-8 [12187481.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7205-9 [15492234.001]
  • [Cites] Int J Cancer. 1983 Jan 15;31(1):13-20 [6339421.001]
  • [Cites] Ophthalmology. 1990 Oct;97(10):1275-80 [2243677.001]
  • [Cites] Curr Eye Res. 1991 May;10(5):479-84 [1889233.001]
  • [Cites] Eur J Cancer. 1996 Feb;32A(2):357-62 [8664054.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4602-9 [16651410.001]
  • (PMID = 20795869.001).
  • [ISSN] 1460-2202
  • [Journal-full-title] Current eye research
  • [ISO-abbreviation] Curr. Eye Res.
  • [Language] ENG
  • [Grant] United States / NEI NIH HHS / EY / P30 EY002687; United States / NCI NIH HHS / CA / R01 CA125970; United States / NCI NIH HHS / CA / R01 CA125970-04; United States / NEI NIH HHS / EY / P30 EY02687C
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / RNA, Messenger
  • [Other-IDs] NLM/ NIHMS337043; NLM/ PMC3230327
  •  go-up   go-down


94. Pan HW, Chou HY, Liu SH, Peng SY, Liu CL, Hsu HC: Role of L2DTL, cell cycle-regulated nuclear and centrosome protein, in aggressive hepatocellular carcinoma. Cell Cycle; 2006 Nov;5(22):2676-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • L2DTL gene expression increased during G1/S phase, and the DNA synthesis in liver regeneration.
  • L2DTL downregulation by RNAi oligos led to reduced cancer cell growth and invasion capability in vitro, in which microarray analysis disclosed dysregulation of genes involved in cell cycle regulation, chromosome segregation, and cell division.
  • L2DTL overexpressed in 59% of 270 resected, unifocal, primary HCCs.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / physiology. Carcinoma, Hepatocellular / metabolism. Cell Cycle. Centrosome / metabolism. Liver Neoplasms / metabolism. Nuclear Proteins / physiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cadherins / metabolism. Down-Regulation. HeLa Cells. Humans. Middle Aged. RNA, Messenger / metabolism. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism. Ubiquitin-Protein Ligases


95. Yan K, Wang YB, Chen MH, Gao W, Yang W, Dai Y, Yin SS: [Prognostic factors on outcome of radiofrequency ablation of 172 primary hepatic tumors]. Zhonghua Yi Xue Za Zhi; 2005 Aug 31;85(33):2322-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factors on outcome of radiofrequency ablation of 172 primary hepatic tumors].
  • OBJECTIVE: To investigate the prognostic factors affecting outcome in Radiofrequency (RF) ablation of primary hepatic tumors by univariate and multivariate analyses, and to assess the therapeutic efficacy of Radio-frequency ablation.
  • METHODS: A total of 172 patients with primary hepatic tumors underwent RF treatment in our department between 1999 and 2004.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Catheter Ablation / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Multivariate Analysis. Prognosis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16321224.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


96. Umeda T, Abe H, Kurumi Y, Naka S, Shiomi H, Hanasawa K, Morikawa S, Tani T: Magnetic resonance-guided percutaneous microwave coagulation therapy for liver metastases of breast cancer in a case. Breast Cancer; 2005;12(4):317-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance-guided percutaneous microwave coagulation therapy for liver metastases of breast cancer in a case.
  • Real-time magnetic resonance (MR) imaging enables the application of percutaneous microwave coagulation for high-risk patients with metastatic liver tumours.
  • MR-guided percutaneous microwave coagulation therapy is effective for treatment of not only primary liver tumours but also metastatic breast cancers in the liver, which are not diffuse but discrete, and difficult to treat with only chemo-and endocrine therapy.
  • We report a 44-year-old Japanese woman who underwent modified radical mastectomy for right breast cancer (T1c N0 M0 Stage I).
  • Three years after the operation, she developed two metastatic liver tumours and was treated by MR-guided percutaneous microwave coagulation, achieving a complete response (CR) without any recurrence for 15 months as of the present.
  • Additional clinical trials will be valuable to delineate the effectiveness and safety of MR-guided percutaneous microwave coagulation therapy for controlling the liver metastases of breast cancer.
  • [MeSH-major] Breast Neoplasms / pathology. Electrocoagulation / methods. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Microwaves / therapeutic use
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Humans. Magnetic Resonance Imaging. Mastectomy, Modified Radical. Treatment Outcome


97. Marrache F, Vullierme MP, Roy C, El Assoued Y, Couvelard A, O'Toole D, Mitry E, Hentic O, Hammel P, Lévy P, Ravaud P, Rougier P, Ruszniewski P: Arterial phase enhancement and body mass index are predictors of response to chemoembolisation for liver metastases of endocrine tumours. Br J Cancer; 2007 Jan 15;96(1):49-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Arterial phase enhancement and body mass index are predictors of response to chemoembolisation for liver metastases of endocrine tumours.
  • Transcatheter arterial chemoembolisation (TACE) has been reported to be an efficient treatment of liver metastases of endocrine tumours in short series of patients.
  • The aim of this work is to identify predictors of response to TACE for liver metastases of endocrine tumours.
  • Primary tumour was located in the pancreas for 19 patients, and had been removed in 43.
  • This large study confirms the previously reported results of TACE regarding its efficacy for the treatment of liver metastases of endocrine tumours.
  • [MeSH-major] Body Mass Index. Chemoembolization, Therapeutic / methods. Endocrine Gland Neoplasms / therapy. Liver Neoplasms / therapy. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Female. Humans. Male. Middle Aged. Multivariate Analysis. Predictive Value of Tests. Retrospective Studies. Sensitivity and Specificity. Streptozocin / adverse effects. Streptozocin / therapeutic use. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. STREPTOZOTOCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Dec;81(8):1351-5 [10604732.001]
  • [Cites] Pancreatology. 2006;6(1-2):77-85 [16327283.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2000 Feb;12(2):151-7 [10741928.001]
  • [Cites] Eur Radiol. 2003 Jan;13(1):136-40 [12541121.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):934-59 [12569593.001]
  • [Cites] N Engl J Med. 2003 Apr 24;348(17):1625-38 [12711737.001]
  • [Cites] Cancer. 2003 Aug 1;98(3):484-95 [12879464.001]
  • [Cites] Cancer J. 2003 Jul-Aug;9(4):261-7 [12967136.001]
  • [Cites] Am J Gastroenterol. 2003 Nov;98(11):2435-9 [14638345.001]
  • [Cites] Endocr Relat Cancer. 2003 Dec;10(4):463-8 [14713259.001]
  • [Cites] Digestion. 2003;68(2-3):94-101 [14593235.001]
  • [Cites] J Clin Oncol. 2004 Feb 1;22(3):439-45 [14691120.001]
  • [Cites] J Clin Oncol. 2004 Feb 1;22(3):446-53 [14691122.001]
  • [Cites] Eur J Cancer. 2004 Mar;40(4):515-20 [14962717.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):648-57 [14966087.001]
  • [Cites] Br J Nutr. 2004 Sep;92(3):347-55 [15469638.001]
  • [Cites] Neuroendocrinology. 2004;80 Suppl 1:74-8 [15477722.001]
  • [Cites] Prog Surg. 1974;13:141-66 [4614326.001]
  • [Cites] N Engl J Med. 1980 Nov 20;303(21):1189-94 [6252466.001]
  • [Cites] Bull Cancer. 1989;76(9):1029-37 [2695182.001]
  • [Cites] Tumour Biol. 1992;13(1-2):27-35 [1317054.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2624-30 [8384072.001]
  • [Cites] Radiology. 1993 Nov;189(2):541-7 [7692465.001]
  • [Cites] Am J Surg. 1995 May;169(5):523-8 [7747834.001]
  • [Cites] Radiology. 1996 Jan;198(1):33-40 [8539401.001]
  • [Cites] Hum Pathol. 1996 Nov;27(11):1124-34 [8912819.001]
  • [Cites] Am J Clin Pathol. 1998 Mar;109(3):286-93 [9495200.001]
  • [Cites] Gut. 1998 Sep;43(3):422-7 [9863490.001]
  • [Cites] Hepatogastroenterology. 2004 Nov-Dec;51(60):1751-6 [15532819.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2434-5; author reply 2435 [15800342.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1668-84 [15887158.001]
  • [Cites] Neuroendocrinology. 2004;80(6):394-424 [15838182.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • (PMID = 17164755.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 5W494URQ81 / Streptozocin; 80168379AG / Doxorubicin
  • [Other-IDs] NLM/ PMC2360220
  •  go-up   go-down


98. Kondili LA, Lala A, Gunson B, Hubscher S, Olliff S, Elias E, Bramhall S, Mutimer D: Primary hepatocellular cancer in the explanted liver: outcome of transplantation and risk factors for HCC recurrence. Eur J Surg Oncol; 2007 Sep;33(7):868-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary hepatocellular cancer in the explanted liver: outcome of transplantation and risk factors for HCC recurrence.
  • AIM: To evaluate the risk of recurrence of hepatocellular cancer (HCC) after liver transplantation (LT).
  • METHODS: The clinical records of 104 patients with HCC in the explanted liver were examined.
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Liver Neoplasms / epidemiology. Liver Transplantation. Neoplasm Recurrence, Local / epidemiology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / blood. Female. Follow-Up Studies. Great Britain / epidemiology. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Prognosis. Proportional Hazards Models. Retrospective Studies. Risk Factors. Survival Rate. alpha-Fetoproteins / metabolism


99. Yu RS, Chen Y, Jiang B, Wang LH, Xu XF: Primary hepatic sarcomas: CT findings. Eur Radiol; 2008 Oct;18(10):2196-205
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary hepatic sarcomas: CT findings.
  • Primary hepatic sarcomas are rare tumors that are difficult to diagnose clinically.
  • Different primary hepatic sarcomas may have different clinical, morphologic, and radiological features.
  • The advent of CT has allowed earlier detection of primary hepatic sarcomas as well as more accurate diagnosis and characterization.
  • In addition, we briefly discuss the MRI findings and diagnostic value of primary hepatic sarcomas.
  • [MeSH-major] Liver / diagnostic imaging. Liver Neoplasms / diagnostic imaging. Sarcoma / diagnostic imaging. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Child. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Magn Reson Imaging. 2004 Jul;22(6):897-900 [15234460.001]
  • [Cites] Korean J Radiol. 2007 Jul-Aug;8(4):343-7 [17673846.001]
  • [Cites] Surg Today. 2002;32(5):446-9 [12061699.001]
  • [Cites] Korean J Radiol. 2007 Mar-Apr;8(2):180-3 [17420638.001]
  • [Cites] Arch Pathol Lab Med. 2001 Mar;125(3):410-2 [11231494.001]
  • [Cites] Radiographics. 2001 Jul-Aug;21(4):895-910 [11452064.001]
  • [Cites] Korean J Gastroenterol. 2006 Jan;47(1):5-14 [16434863.001]
  • [Cites] Radiology. 2006 Jul;240(1):295-8 [16793987.001]
  • [Cites] J Comput Assist Tomogr. 1997 Jan-Feb;21(1):100-2 [9022777.001]
  • [Cites] Cancer. 1999 Feb 1;85(3):562-82 [10091730.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2006 Nov;5(4):620-3 [17085355.001]
  • [Cites] Radiographics. 1994 Jan;14 (1):153-66; quiz 167-8 [8128048.001]
  • [Cites] World J Gastroenterol. 2006 Feb 21;12(7):1157-9 [16534865.001]
  • [Cites] AJR Am J Roentgenol. 1998 Sep;171(3):900-1 [9725359.001]
  • [Cites] Clin Radiol. 1993 Nov;48(5):321-5 [8258223.001]
  • [Cites] AJR Am J Roentgenol. 1989 Jan;152(1):63-72 [2535770.001]
  • [Cites] AJR Am J Roentgenol. 1993 Dec;161(6):1331-2 [8249754.001]
  • [Cites] Magn Reson Imaging. 1993;11(1):139-43 [8380881.001]
  • [Cites] Hepatology. 2001 Mar;33(3):647-51 [11230745.001]
  • [Cites] Acta Radiol. 2007 Dec;48(10):1061-5 [18038349.001]
  • [Cites] Radiographics. 2005 Sep-Oct;25(5):1371-95 [16160117.001]
  • [Cites] Radiology. 1997 Jun;203(3):779-83 [9169704.001]
  • [Cites] Clin Imaging. 1996 Oct-Dec;20(4):273-5 [8959367.001]
  • [Cites] Cancer. 2007 Apr 1;109(7):1391-6 [17315167.001]
  • [Cites] Radiology. 1988 Oct;169(1):145-8 [3420251.001]
  • [Cites] AJR Am J Roentgenol. 2000 Jul;175(1):165-70 [10882268.001]
  • [Cites] Radiat Med. 2006 Jun;24(5):369-72 [16958416.001]
  • [Cites] Cancer. 1978 Jul;42(1):336-48 [208754.001]
  • [Cites] Chin Med J (Engl). 2004 Oct;117(10):1586-7 [15498391.001]
  • [Cites] Arch Pathol Lab Med. 1985 Sep;109(9):853-7 [3927870.001]
  • [Cites] Abdom Imaging. 1999 Jul-Aug;24(4):386-91 [10390563.001]
  • [Cites] AJR Am J Roentgenol. 1992 Jul;159(1):53-7 [1302463.001]
  • [Cites] Dig Dis Sci. 2003 Apr;48(4):677-82 [12741455.001]
  • [Cites] Gastrointest Radiol. 1992 Winter;17(1):58-62 [1544560.001]
  • [Cites] Eur Radiol. 2000;10(1):129-33 [10663729.001]
  • [Cites] Radiology. 2002 Mar;222(3):667-73 [11867783.001]
  • [Cites] Am J Surg Pathol. 2007 Jun;31(6):817-26 [17527068.001]
  • [Cites] Cancer Imaging. 2005 Aug 23;5:89-94 [16154826.001]
  • [Cites] Am J Gastroenterol. 1995 Apr;90(4):649-52 [7717329.001]
  • [Cites] World J Surg Oncol. 2006 Feb 20;4:9 [16504010.001]
  • [Cites] Radiology. 1989 Apr;171(1):63-8 [2648478.001]
  • [Cites] Mt Sinai J Med. 2005 Jan;72(1):50-2 [15682264.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):252-7 [11815984.001]
  • [Cites] J Clin Ultrasound. 2001 Jan;29(1):44-7 [11180184.001]
  • [Cites] Pediatr Transplant. 2001 Oct;5(5):365-9 [11560757.001]
  • [Cites] Eur J Radiol. 1995 Mar;19(3):177-82 [7601167.001]
  • [Cites] Abdom Imaging. 1996 Mar-Apr;21(2):157-60 [8661764.001]
  • [Cites] World J Gastroenterol. 2005 Feb 14;11(6):926-9 [15682496.001]
  • [Cites] Clin Radiol. 1998 Sep;53(9):699-701 [9766725.001]
  • [Cites] Cancer. 1982 Sep 1;50(5):970-81 [7093931.001]
  • [Cites] AJR Am J Roentgenol. 2003 May;180(5):1359-64 [12704052.001]
  • [Cites] Magn Reson Imaging Clin N Am. 1997 May;5(2):397-413 [9113682.001]
  • (PMID = 18463872.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 53
  •  go-up   go-down


100. Rajaganeshan R, Prasad R, Guillou PJ, Chalmers CR, Scott N, Sarkar R, Poston G, Jayne DG: The influence of invasive growth pattern and microvessel density on prognosis in colorectal cancer and colorectal liver metastases. Br J Cancer; 2007 Apr 10;96(7):1112-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The influence of invasive growth pattern and microvessel density on prognosis in colorectal cancer and colorectal liver metastases.
  • The nature of the invasive growth pattern and microvessel density (MVD) have been suggested to be predictors of prognosis in primary colorectal cancer (CRC) and colorectal liver metastases.
  • Archival tissue was retrieved from 55 patients who had undergone surgical resection for primary CRC and matching liver metastases.
  • Primary CRCs with a pushing margin tended to form capsulated liver metastases (P<0.001) and had a significantly better disease-free survival than the infiltrative margin tumours (log rank P=0.01).
  • Primary cancers with a high MVD tended to form high MVD liver metastases (P=0.007).
  • Microvessel density was a significant predictor of disease recurrence in primary CRCs (P=0.006), but not liver metastases.
  • These results suggest that primary CRCs and their liver metastases show common histological features.
  • [MeSH-major] Adenocarcinoma / secondary. Colorectal Neoplasms / blood supply. Colorectal Neoplasms / pathology. Liver Neoplasms / secondary. Neovascularization, Pathologic / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD31 / metabolism. Disease-Free Survival. Female. Humans. Male. Microcirculation. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Prognosis. Survival Rate






Advertisement